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Monoclonal Gammopathy of Undetermined Significance (MGUS) is an understudied 
precursor of multiple myeloma (MM), the second most prevalent hematologic 
malignancy in the United States. This dissertation was designed to: (1) Describe the 
trajectories of serum biomarkers over time in patients with an MGUS diagnosis, (2) 
Determine if an MGUS diagnosis is associated with changes in healthcare service 
utilization, and (3) explore the patient- and provider-level drivers of healthcare utilization 
in patients with MGUS. 
 
Methods 
Data sources include health claims and electronic health records from a community-based 
population of patients seeking care in central Massachusetts and primary qualitative data 
collected from providers and patients’ interviews. The analyses included descriptive 
statistics, group-based trajectory modeling, conditional Poisson regression, and 






(1) Three distinct multi-trajectory groups of creatinine and hemoglobin were identified. 
(2) The rates of emergency room, hospital, and outpatient visits were higher for patients 
with MGUS than patients without MGUS. (3) Patients have a basic understanding of 
MGUS; however, some patients feel anxiety, which may affect other aspects of their 
lives. Patients primarily see hematologists for follow-up care; other providers have less 
knowledge about MGUS.  
 
Conclusions 
Biomarker trajectories characterize specific subpopulations of patients with MGUS over 
time. We found that an MGUS diagnosis is associated with higher healthcare utilization, 
especially during the months surrounding the diagnosis date. Finally, our study suggests 
that some patients with MGUS may need psychosocial support services and identifies a 
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CHAPTER I: INTRODUCTION 
 
EPIDEMIOLOGY OF MULTIPLE MYELOMA 
 
Multiple myeloma is the second most commonly diagnosed hematologic 
malignancy in the US.1–3 In 2021, approximately 34,920 new cases of multiple myeloma, 
a malignancy of plasma cells, will be diagnosed, and nearly 12,410 deaths from multiple 
myeloma are expected to occur in the US.4–6 Multiple myeloma is difficult to diagnose in 
early stages because it is usually asymptomatic.7 In its more advanced stages, symptoms 
include anemia, bone fracture, calcium deficiencies, infections, and kidney dysfunction.7 
In the past decade, overall multiple myeloma survival rates have improved significantly. 
Patients diagnosed with this malignancy in the US had a 5-year survival rate of only 25-
30% in the late 1970s,8 whereas expected survival has doubled to 52.2% approximately 
40 years later,9 most likely due to the development and availability of effective 
therapies.10–13 However, there is evidence of racial disparities in multiple myeloma 
incidence and mortality, and improvements in multiple myeloma survival have been 
differentially observed in racial/ethnic groups in the US.14 Non-Hispanic White patients 
have experienced the greatest improvements in survival, followed by African-Americans, 
although the reasons for these disparities are not fully understood.15 Differences in 
patterns of healthcare access and utilization may explain why non-Hispanic White 
patients experience better survival outcomes than patients of other races and ethnicities.16  
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OVERVIEW OF MONOCLONAL GAMMOPATHY OF UNDETERMINED 
SIGNIFICANCE (MGUS) 
 
Monoclonal Gammopathy of Undetermined Significance (MGUS) is an early 
pathogenic step in the development of multiple myeloma.17 MGUS is a plasma cell 
disorder characterized by the overproduction of monoclonal protein.17 MGUS is usually 
an asymptomatic condition incidentally diagnosed through blood tests.18 The healthcare 
cost of MGUS follow-up in the US alone is likely to be more than $100 million 
annually.19 In the US, MGUS prevalence has been estimated at 2 to 3% among 
individuals 50 years and older and approximately 5% in persons 70 years and older, 
although most cases are undiagnosed.20 Older adults, men, and people of African descent 
in the US are at higher risk of MGUS than respective comparison groups.21 Each year, 
approximately 1% of patients with MGUS develop multiple myeloma;22 however, few 
risk factors for progression are known, and the majority of patients live for many years 
without developing multiple myeloma.22 Patients with MGUS are also at increased risk 
for developing other lymphoproliferative conditions including Waldenström 
macroglobulinemia, lymphoma, and amyloidosis.23 Patients with MGUS do not undergo 
treatment until the disease progresses into multiple myeloma. However, patients with 
multiple myeloma who had a previous clinical MGUS diagnosis (median survival, 2.8 
years) have better long-term survival than those without a prior diagnosis (median 
survival, 2.1 years).24 The reasons why a prior MGUS diagnosis could lead to better 
survival in multiple myeloma patients remains unclear. 
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GUIDELINES FOR MONITORING AND MANAGEMENT 
 
There are no clear standard recommendations for MGUS clinical follow-up. For 
patients with a diagnosis of MGUS, optimal clinical follow-up, including the frequency 
of visits and the type of ancillary tests to order, is unknown.25 There are four international 
clinical practice guidelines for MGUS, all based on expert consensus, yet their 
recommendations vary widely.26–29 The United Kingdom Myeloma Forum and Nordic 
Myeloma Study Group (UK-Nordic)26 and the international expert consensus (IEC)27 
recommend more aggressive follow-up patterns than the International Myeloma Working 
Group (IMWG)30 and the European Myeloma Network (EMN),28 which offer more 
conservative guidelines. In general, these guidelines suggest, depending on the individual 
patient’s characteristics, life-long monitoring every 6 to 12 months of individuals to 
detect progression to multiple myeloma or related disorders.26–29 For example, low-risk 
(i.e., a < 30 g/L of M protein on serum protein electrophoresis test) MGUS requires less 
frequent monitoring than patients in higher risk strata.24 The most commonly used 
diagnostic tests for MGUS are serum or urine protein electrophoresis (SPE), 
immunofixation, and in more recent years, serum free light chain testing (SFLC).31  
 
FOLLOW-UP PATTERNS IN THE UNITED STATES 
 
In the US, MGUS follow-up patterns vary by geographic region, sex, gender, and 
age.32,33 Patients ≥80 years old were more likely to be followed up at intervals of <6 
months while patients ≥60 years were followed up at intervals of <13 months.32 Also, 
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patients from the Northeastern US were more likely to be followed up at intervals >24 
months, which is longer than any other US region.32 Approximately half the patients with 
MGUS diagnosed in 2013 lacked concordance with any of the clinical practice 
guidelines.33 The role of other clinical characteristics, such as diagnosed comorbidities, in 
clinical follow-up patterns is not well established, mainly because MGUS is incidentally 
diagnosed, and people with other chronic conditions may be more likely to be diagnosed 
with MGUS as a result of frequent encounters with the healthcare system.34 In the first 
aim of this dissertation, we characterized trajectories of change in creatinine and 
hemoglobin laboratory values to identify subgroups of patients with MGUS with certain 
patterns of common clinical biomarkers over time.  
 
THE IMPACT OF A DIAGNOSIS OF MGUS ON HEALTHCARE UTILIZATION 
 
Patients may experience high distress after a diagnosis of premalignant MGUS.35–
37 This associated anxiety could result in a change (overutilization/underutilization) in 
healthcare utilization and clinical surveillance beyond what is necessary.38 Quantifying 
the care and surveillance of patients with MGUS is of clinical relevance given that 
multiple myeloma patients with a pre-existing MGUS diagnosis have been shown to have 
a better multiple myeloma prognosis. Healthcare utilization patterns by MGUS patients 
may provide insight into preventative healthcare measures that may improve their overall 
health and result in prolonged survival.39 Therefore, in the second aim of this dissertation 
we investigated the role of an MGUS diagnosis in healthcare utilization patterns in order 
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to obtain insight into why patients with MGUS might have better long-term survival. 
Studies have shown that cancer patients have better outcomes if they had more utilization 
of primary care preceding the cancer diagnosis.40–43 To our knowledge, no studies have 
evaluated the impact of an MGUS diagnosis on overall health service utilization, 
including emergency department, hospital and outpatient visits. Patients with MGUS 
have frequent outpatients visits25 possibly due in part to higher stress after this diagnosis, 
and concern about progressing to multiple myeloma. This dissertation investigated 
specific health services used during these follow-up visits, with the goal of elucidating 
factors and practices that may contribute to a patient’s overall prognosis.33 
 
PATIENT AND PROVIDER PERCEPTIONS 
 
Finally, patient and provider perceptions of MGUS may be divergent. Based on 
prior work providers may describe MGUS to their patients with simple terminology such 
as “abnormal protein” and use analogies such as comparing the protein found in the blood 
(paraprotein) to the finding of a mole or lump.44 In addition, providers have previously 
been found to include the terms premalignant, precancer or cancer less frequently when 
explaining MGUS to their patients. Patients’ education level, age and cognitive ability 
have been shown to be important factors to providers in deciding how and whether 
information was relayed to patients.44 In addition, it is important to understand patients’ 
experiences after a diagnosis of MGUS. There is, however, a lack of data evaluating 
patient and healthcare provider responses to a new diagnosis of MGUS, which may 
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impact patients’ healthcare utilization after the MGUS diagnosis. In our third aim, we 
seek to provide insight into the reasons for patients’ healthcare utilization practices 
overall and related to MGUS and allow for the exploration of patient- and provider-level 
drivers behind patterns of healthcare utilization in addressing MGUS. 
 
This dissertation had the overall goal of evaluating factors contributing to 
healthcare utilization in a population diagnosed with a premalignant condition and 
elucidate potential targets to improve long-term survival of MGUS patients. The specific 
aims were:  
 
AIM 1 
Describe laboratory value trajectories of patients with MGUS diagnosed in a community-
based practice in central Massachusetts.  
 
Hypothesis 1: Distinct longitudinal trajectories of values from commonly used laboratory 
tests (e.g. serum creatinine) will emerge in MGUS patients. 
 
AIM 2 
Determine if an MGUS diagnosis is associated with changes in healthcare utilization 
(e.g., emergency department hospital, and outpatient visits) that differ according to 
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patients’ sociodemographic and clinical characteristics as compared to a population 
without MGUS.  
 
Hypothesis 2: Compared to a comparison group matched on age, sex, and length of 
enrollment in the health system, as well as the time period before diagnosis, patients with 
MGUS will have increased healthcare utilization after MGUS diagnosis. 
 
AIM 3 
Explore the patient- and provider-level drivers of healthcare utilization in patients with 
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CHAPTER II: MULTI-TRAJECTORY MODELS OF SERUM BIOMARKERS 






Understanding the progression of monoclonal gammopathy of undetermined 
significance (MGUS) to multiple myeloma (MM) is needed to identify patients who 
would benefit from closer clinical surveillance. Given that two of the defining criteria of 
multiple myeloma are renal failure and anemia, we described the trajectories of creatinine 
(Cr) and hemoglobin (Hgb) over time in patients with a diagnosis of MGUS. 
 
Methods 
Patients diagnosed with MGUS (n=424) were identified by a previously validated 
case-finding algorithm using health claims and electronic health record data (2007-2015) 
and followed through 2018. Group-based trajectory modeling identified patients with 
distinct laboratory value trajectories of Cr (mg/dL) and Hgb (mg/dL).  
 
Results 
Most were non-Hispanic White (97.6%) with a mean age of 75 years at MGUS 
diagnosis. Three multi-trajectory groups were identified: 1) Normal Cr/Hgb (53.1%) -
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stable serum Cr levels and decreasing, normal Hgb levels; 2) Normal Cr/lower-normal 
Hgb group (44.3%) - stable, slightly elevated levels of Cr and decreasing, slightly low 
levels of Hgb; and 3) High Cr/borderline Hgb group (2.6%) - increased Cr levels and 
stable low levels of Hgb. Patients with MGUS in the normal Cr/lower-normal Hgb group 
were older, more likely to have a prior cancer diagnosis, and had more comorbidities than 
participants in the normal Cr/Hgb group. Twenty-one patients developed multiple 
myeloma during the study period (normal Cr/Hgb: 3%, normal Cr/lower-normal Hgb: 
7%, high Cr and borderline Hgb: 9%). 
 
Conclusion 
Biomarker trajectories characterize specific subpopulations of patients with 
MGUS over time. Future research should further investigate how these trajectories may 
be related to the risk of progression to multiple myeloma, including M-protein levels.  
 
  





Multiple myeloma (MM) is the second most commonly diagnosed hematologic 
malignancy in the United States. 1–3 Monoclonal gammopathy of undetermined 
significance (MGUS) is an early pathogenic step in the development of multiple 
myeloma, and a risk factor for other malignancies, including lymphoma, light chain 
amyloidosis, and Waldenström macroglobulinemia.17,45,46 While 3% of adults over the 
age of 50 years may have clinical evidence of MGUS,30,47–51 the vast majority remain 
undiagnosed, as MGUS is mostly asymptomatic and almost always diagnosed 
incidentally.24,45,52 Patients with MGUS progress to multiple myeloma at a rate of 
approximately 1% annually.22,53,38 Despite the relatively low risk of progression, patients 
with a diagnosis of MGUS are generally followed up every 6-12 months for signs of 
progression to malignancy.35–37 
 
It is not currently possible to predict which patients with MGUS are more likely 
to progress to multiple myeloma.54 Elevated monoclonal (M)-protein concentration, 38 
immunoglobulin M or A isotype,38 abnormal bone marrow plasma cells 55,56 and 
abnormal free light chain ratios are risk factors for progression of MGUS to multiple 
myeloma.57 Gaining a better understanding of factors related to the progression of MGUS 
to multiple myeloma is essential to identify patients at greater risk of progression and 
provide insights into which patients with MGUS will benefit from closer surveillance.  
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The absence of end-organ, as damage defined by the CRAB criteria 
(hyperCalcemia, Renal insufficiency, Anemia, lytic Bone lesions) is a key clinical feature 
distinguishing MGUS from multiple myeloma.58 Two of the critical defining criteria of 
multiple myeloma are renal failure (as measured by creatinine (Cr) > 2.0 mg/dl) and 
anemia (hemoglobin (Hgb) < 10 g/dL).45,59 Discerning disease patterns through the use of 
rigorous statistical models has the potential to identify distinct subgroups of patients. 
Using data from patients seeking care at a large provider group in central Massachusetts, 
we used group-based trajectory modeling (GBTM) to identify groups of patients with 
MGUS who shared similar trajectories over time of two commonly measured biomarkers 
indicative of renal failure and anemia, Cr and Hgb. A secondary study goal was to 
examine differences in patient characteristics among patients diagnosed with MGUS with 
varying biomarker trajectories. 
  





Study Participants and Settings 
The Institutional Review Board of the University of Massachusetts Medical 
School approved this study. It was conducted in the Meyers Primary Care Institute 
(MPCI), a joint research endeavor of the University of Massachusetts Medical School 
(UMMS), Fallon Health, an insurer, and Reliant Medical Group, a community-based 
multispecialty provider organization. A standardized data resource comprised of 
electronic health records (EHR) and health claims data for patients receiving care at 
Reliant Medical Group from January 1, 1999, through December 31, 2018, was used to 
identify the study population.60 Cancer diagnoses through 2016 were identified using 
tumor registry data obtained from the Massachusetts Cancer Registry (1999-2016) and 
the in-house tumor registry at Reliant (2010-2016). 
 
Study Population 
This analysis included individuals diagnosed with MGUS who were identified by 
applying a case-finding algorithm to the EHR-based database, as previously described 
elsewhere.61 Briefly, the algorithm first identified all eligible patients aged 50 years and 
older with ≥2 ICD-9 diagnosis codes for MGUS (273.1) entered on different dates within 
12 months between 2007 and 2015. Next, patients were selected who, within 90 days of 
MGUS diagnosis, had at least one code for a serum or urine protein electrophoresis test 
(Current Procedural Terminology (CPT) code 84155 or 84156), at least one serum or 
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urine immunofixation test (CPT 86334 or 86335), and an in-office hematology/oncology 
visit. Patients met the algorithm criteria if the corresponding CPT code was present in 
their EHR within the specified time frame. The algorithm identified 429 cases of MGUS 
and 424 had at least two measures of Cr and Hgb (Supplemental Figure 1).  
 
Covariates 
The first appearance of the ICD‐9 diagnosis code for MGUS (273.1) in a patient's 
EHR was considered the diagnosis date. The following characteristics were assessed at 
diagnosis date: age, sex (male and female), and race (non-Hispanic White, non-Hispanic 
Black and other race/ethnicities), Charlson comorbidity index (continuous [0-15 score]; 
and categorical [0,1, 2+] scores),62 smoking status (never, current, or quit/former/passive 
smokers), body mass index (BMI) (underweight [<18.5 kg/m2], normal [18.5-25 kg/m2], 
overweight [25-30 kg/m2], obese [≥30 kg/m2]), alcohol use (never and current), and 
census tract-level socioeconomic index (low, medium, high). The Charlson comorbidity 
index score was calculated based on ICD-9/10 codes in the year before the MGUS 
diagnosis date. Those patients without any of the ICD codes included in the Charlson 
comorbidity index were assigned the value of zero (Supplemental Table 1). The census 
tract-level socioeconomic index was calculated using factor analysis of median household 
income, median house rent, percentage of the population living below 150% of the 
poverty line, education index, and percent unemployed. We calculated the tertiles of 
socioeconomic index values (i.e., first tertile = low neighborhood SES, the second tertile 
= medium neighborhood SES, third = high neighborhood SES).63 All data were derived 
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from the EHR and claims data of MGUS cases. To account for missing data related to 
tobacco use, alcohol use, and BMI, we imputed values by carrying forward the last 
available observation closest to the MGUS diagnosis date.64 
 
Laboratory values 
We evaluated the trajectories of the laboratory results of serum Cr and Hgb tests. 
We collected all available measures of these laboratory test values through the review of 
the patients' EHR collected over three years after MGUS diagnosis for each patient. The 
primary analysis focused on measurements collected on or after the patient’s date of 
MGUS diagnosis. All outcome variables (Cr and Hgb) were averaged every six months 
from diagnosis date to deal with the relative scarcity of data and infrequency of the 
laboratory measurements. This procedure also yields measurements on a discrete time 
scale required by the GBTM.  
 
Statistical Analysis 
Descriptive statistics were used to evaluate the sociodemographic and clinical 
characteristics of patients with MGUS. We performed a multi-trajectory analysis using 
the TRAJ procedure in Stata 16.65 A series of group-based trajectory models were 
separately fitted and compared to determine the optimal number of subgroups defined by 
serum Cr and Hgb levels, and models with 2-5 groups were analyzed. We started the full 
model with cubic polynomials and then reduced the order of each group until the 
parameters of the trajectories were statistically significant (p-value <0.05). For each 
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model, we obtained the fit statistics (Bayesian Information Criterion, Akaike Information 
Criterion, and Log-Likelihood), the proportion of patients assign to each trajectory group 
and the mean posterior probability for each group. After considering model fit, 
parsimony, and clinical relevance, we considered the best-fitting model for Cr and Hgb 
separately, given that for Cr the best model was a four-group model and for Hgb the best 
was a three-group model (Data not shown). Then, we fit models with three and four 
multi-trajectory groups evaluating both outcomes (Cr and Hgb) together. This approach 
fits a semiparametric (discrete) mixture model to longitudinal data using the maximum 
likelihood function where each resultant joint trajectory is a combination of the individual 
trajectories for Cr and Hgb. After comparing the model selection statistics and graphical 
representation, we considered that the most parsimonious model was the one with three 
group trajectories. The final orders of polynomials for Cr were one group with a cubic 
and two groups with intercept, and for Hgb the order for all three groups were cubic. 
Patients with MGUS were assigned to the trajectory groups for which they had the 
highest posterior probabilities as predicted by the model. We assigned qualitative labels 
to describe each group based on the overall patterns of Cr and Hgb trajectories. 
Multinomial logistic regression was used to identify the bivariate associations of group 
trajectories (outcome) with characteristics at time of diagnosis (predictors). Logistic 
regression model were used to evaluate the association of multiple myeloma (outcome) 
and trajectory groups (predictor). The models are also adjusted for comorbidity index and 
age. As a sensitivity analysis, we repeated all analyses with the subset of 154 identified 
MGUS cases validated by a targeted chart review.  





Study population characteristics 
The 424 patients with MGUS had a median (IQR) follow-up time of 22 (12-31) 
months, with 71% (Hgb) to 75% (Cr) of patients with lab test results had at least three 
years of follow-up. Of the identified MGUS cases, nearly half were female, most were 
non-Hispanic White, and the mean age at MGUS diagnosis was 75.0 years. Eleven 
percent were current smokers, 46.3% were current alcohol users, and 70% were 
overweight or obese. The majority of patients with MGUS did not have a previous 
diagnosis of cancer and had a median Charlson comorbidity index of 2.3 (Table 1).  
 
Predicted multi-trajectory groups of creatinine and hemoglobin laboratory values 
The median number of repeat tests for Hgb was 6 (range: 2-6) and for Cr, 6 
(range: 2-6) tests per participant. Three distinct multi-trajectory groups were identified 
(Figure 1). Patients in the Normal Cr/Hgb group (n= 225, 53.1%) showed stable normal 
levels of serum Cr over time (mean: 1.1 mg/dL) and a slight decrease in mean Hgb levels 
of approximately 0.1 mg/dL per year on average. The Normal Cr/ Lower-normal Hgb 
group (n= 188, 44.3%) showed stable normal levels of serum Cr over time (mean: 1.4 
mg/dL) and slight decrease in mean Hgb levels of approximately 0.01 mg/dL per year on 
average. Patients in the High Cr/ borderline Hgb group (n= 11, 2.6%) had increases of 
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approximately 1.0 mg/dL per year on average in Cr and decreasing levels of Hgb over 
time. 
 
Predictors of group membership of creatinine and hemoglobin trajectories 
Patients with MGUS in the normal Cr/Hgb group (N = 225; mean = 72 years) 
were younger than patients with MGUS in the normal Cr / lower-normal Hgb group (N = 
188; mean = 79 years, p-value = 0.0001). However, the age at diagnosis of patients with 
MGUS in the normal Cr/Hgb group is not statistically different from patients with MGUS 
in the high Cr/ borderline Hgb group (N = 11; mean = 69 years; p-value=0.385). Patients 
with MGUS in the normal Cr/Hgb group had lower mean Charlson comorbidity score 
(mean Charlson score = 1) than patients in the normal Cr / lower-normal Hgb group 
(mean Charlson score = 3, p-value=0.001). Patients with MGUS in the normal Cr/Hgb 
group also had a lower mean Charlson score than patients in the high Cr/ borderline Hgb 
group (mean score = 6, p-value=0.0001; Table 2).  
 
Progression to multiple myeloma by trajectory group 
In an exploratory analysis examining a limited number of multiple myeloma 
diagnoses among study participants (with an average of 10 years of follow-up), 21 
patients developed multiple myeloma after MGUS diagnosis. Six multiple myeloma 
cases were in the normal Cr/Hgb group, fourteen were in the normal Cr/ lower-normal 
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Hgb group, and one was in the high Cr/ borderline Hgb group. We constructed a logistic 
regression model with multiple myeloma as the outcome and trajectory group as the main 
independent variable to explore a possible association, although precision was low. After 
adjusting for Charlson comorbity index and age at diagnosis, patients in the high Cr / 
borderline Hgb group (aOR: 5.22, 95% CI = 1.78-15.32) and normal Cr / lower-normal 
Hgb group (aOR: 12.28; 95% CI = 1.03-146.05) were more likely to eventually be 
diagnosed with multiple myeloma than patients in the normal Cr/Hgb group (Table 3).  
 
Sensitivity analysis with validated MGUS 
Analyses on the subset of 154 patients whose MGUS diagnosis was validated via 
a chart review are shown in Supplemental Figure 1-2, Supplemental Tables 2-3. 
Qualitatively, the findings were similar in the group of patients with validated MGUS as 
with the larger sample. 
 
  





In this study, we identified three distinct groups of patients with MGUS sharing 
similar trajectories of Cr and Hgb laboratory values over the three years following a 
diagnosis of the premalignant, yet asymptomatic condition MGUS. We found that few 
patients transitioned to multiple myeloma. Guidelines for monitoring patients with 
MGUS encourage clinicians to track certain blood markers every 6-12 months, including 
M-protein levels, that may indicate progression to malignancy. However, there are four 
existing international guidelines for the clinical surveillance of patients with MGUS, and 
specific recommendations vary.26–29 
 
In the US, MGUS follow-up practice patterns vary by geographic region, sex, and 
age.32,33 A recent study observed that patients aged ≥80 years old with an MGUS 
diagnosis were more likely to be followed clinically at intervals of <6 months, while 
patients ≥60 years were followed up at intervals of >13 months. 32 Patients from the 
northeastern US were more likely to be followed up at intervals >24 months, which is 
longer than any other US region.32 Approximately half the patients with MGUS 
diagnosed in 2013 in the US lacked concordance with any of the clinical practice 
guidelines.33 Our study was conducted in Massachusetts and as such may be limited by 
longer follow-up intervals typical in the northeast region of the US. 33 
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The most common tests for diagnosing patients with MGUS are serum or urine 
protein electrophoresis, immunofixation, and in more recent years, serum free light chain 
testing.3,1 In addition, Cr and complete blood cell count tests are recommended as part of 
regular clinical surveillance to monitor potential organ damage indicative of disease 
progression.26–29 The ability to identify longitudinal patterns of these laboratory values 
could help define additional, informative criteria to follow-up in these patients. 
 
To the best of our knowledge, this study is the first study to simultaneously model 
Cr and Hgb levels among patients with MGUS. We were unable to evaluate M protein 
levels in this population, as relevant results generally appear as text, and were not 
available in our EHR-based datasets. The three groups identified by our models are 
characterized by distinct trajectories and patient demographic characteristics. A previous 
study among patients with smoldering multiple myeloma found decreased trajectories for 
Hgb associated with a decreased median time to progression.66 However, no studies have 
evaluated trajectories of Cr levels among patients with a multiple myeloma precursor 
condition, or modeled the two biomarkers together.  
 
Study Strengths and Limitations 
This study has several strengths, including the use of a large, standardized 
electronic database of claims and EHR data. This database allowed us to obtain objective 
measurements and longitudinal follow-up. In addition, the utilization of a validated 
MGUS algorithm allowed for the identification of patients with MGUS in a community‐
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based setting with reasonable accuracy.61 In addition, we used GBTM,65 a tool that has 
been increasingly adopted in clinical research, to model the development of a clinically 
important indicator over time, with the goal of identifying groups of individuals sharing a 
common trajectory.67 The limitations that should be considered in the interpretation of the 
results include the generalizability to other populations (the majority of this population 
were non-Hispanics White patients, and all had access to healthcare) and the limited 
sample size. We were unable to validate all MGUS cases identify by the algorithm, 
however a sensitivity analysis of validate MGUS cases by EHR review (n=154) yielded 
similar results. In addition, we did not independently verify the EHR-derived data present 
in the datasets, and we acknowledge the possibility of wrongly encoded lab values. We 
were also unable to assess other important relevant laboratory values including M-protein 
levels which were not captured in the database. Cancer diagnoses were only available 
through 2016. At this time, we cannot apply the trajectory models reported in this study 
to predict the risk of progression to multiple myeloma for a patient with MGUS. Future, 
larger studies are needed to specifically develop methodologies to accurately predict 
patients’ risk of progression to multiple myeloma, including identifying early signs of 
multiple myeloma progression. 
 
Conclusion  
This study shows that GBTM can be used to identify sub-groups of patients with 
MGUS with distinct trajectories of important disease biomarkers. Future research should 
further investigate how these trajectories may be related to the risk of progression to 
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multiple myeloma, including M-protein levels. Furthermore, our study revealed distinct 
clinical and sociodemographic factors related to trajectory group. If validated in larger 
diverse populations with more MGUS cases the trajectories could be refined and included 
additional biomarkers such as M-protein and help in the development of better 
surveillance guidelines for patients with MGUS.  
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TABLES AND FIGURES 
 
Table 1. Sociodemographic and clinical characteristics at MGUS diagnosis of 
patients with MGUS 
Characteristic 
Patients with MGUS 
(n=424) 
Men, n (%) 216 (50.9) 
Age at index date (Mean ± S.D.), years 75.0 ± 10.4 
Race, n (%)  
     Non-Hispanic White 364 (97.6) 
     Non-Hispanic Black 6 (1.6) 
     Other 3 (0.8) 
Socioeconomic index, n (%) a  
     Low 82 (37.8) 
     Medium 63 (28.6) 
     High 75 (34.1) 
Tobacco use, n (%)  
     Never 149 (38.2) 
     Current smokers 42 (10.8) 
     Quit/Former/Passive Smokers 199 (51.0) 
Current alcohol use, n (%) b 149 (46.3) 
Body mass index, n (%)  
     Underweight (<18.5 kg/m2) 6 (1.7) 
     Normal (18.5-25 kg/m2) 102 (28.4) 
     Overweight (25-30 kg/m2) 141 (39.3) 
     Obese (≥30 kg/m2) 110 (30.7) 
Previous cancer diagnosis, n (%) c  
     Breast (among women) 11(5.2) 
     Prostate (among men) 13 (6.0) 
     Blood d 4 (0.9) 
     Other 15 (3.5) 
Charlson comorbidity index, n (%) e  
     0 108 (25.5) 
     1 78 (18.4) 
     ≥ 2 238 (56.1) 
     Mean ± SD 2.3 ± 2.3 
Mean serum Cr levels, (± S.D.), mg/dl f 1.3 ± 1.0 
Mean serum Hgb levels, (± S.D.), mg/dl g 12.5 ± 1.5 
May not total 100% due to rounding. Cr=creatinine; Hgb= Hemoglobin. Missing values: Race (n=51), socioeconomic status index 
(n=204), tobacco (n=34), alcohol (n=102), body mass index (n=65) a Tertiles of factor score of median household income, 
median house rent, percentage of the population living below 150% of the poverty line, education index, and percent 
unemployed; b Current vs never c presence of ICD-O-3 code in tumor registry data prior to MGUS diagnosis; d Includes multiple 
myeloma, leukemia, lymphoma; e Using a modified Charlson score with 15 components; f Normal levels less than 2mg/d; `g Normal 
levels between 12 and 15 mg/dl
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Figure 1. Multi-trajectories of creatinine and hemoglobin among 424 patients with MGUS identified through EHR data 
 
The dashed-line (----) represents the cut-off point for the definition of abnormal values for each biomarker. Renal insufficiency 
is defined as creatinine (Cr) levels >2 mg/dl. Anemia is defined as hemoglobin (Hgb) levels <10 mg/dL.  
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Total, n (%) 225 (53.1) 188 (44.3) 11 (2.6) 
Men, n (%) 121 (53.8) 88 (46.8) 7 (63.6) 
Age at index date (Mean ± S.D.), years 72.1 ± 10.5 78.8 ± 8.7 69.3 ± 10.2 
Race, n (%)    
     Non-Hispanic White 203 (96.7) 155 (98.7) 6 (100) 
     Non-Hispanic Black 4 (1.9) 2 (1.3) 0 
     Other 3 (1.4) 0 0 
Socioeconomic index, n (%) a    
     Low 44 (36.7) 36 (38.7) 2 (28.6) 
     Medium 31 (25.8) 30 (32.3) 2 (28.6) 
     High 45 (37.5) 27 (29.0) 3 (42.9) 
Tobacco use, n (%)     
     Never 79 (38.5) 67 (38.5) 3 (27.3) 
     Current smokers 30 (14.6) 10 (5.7) 2 (18.2) 
     Quit/Former/Passive Smokers 96 (46.8) 97 (55.7) 6 (54.5) 
Current alcohol use, n (%) b 95 (54.9) 53 (37.1) 1 (16.7) 
Body mass index, n (%)    
     Underweight (<18.5 kg/m2) 2 (1.0) 4 (2.5) 0 
     Normal (18.5-25 kg/m2) 56 (29.5) 45 (28.1) 1 (11.1) 
     Overweight (25-30 kg/m2) 79 (41.6) 58 (36.2) 4 (44.4) 
     Obese (≥30 kg/m2) 53 (27.9) 53 (33.1) 4 (44.4) 
Previous cancer diagnosis, n (%) c    
     Breast (Among women) 3 (2.9) 7 (7.0) 1 (9.1) 
     Prostate (Among men) 3 (2.5) 9 (10.2) 1 (9.1) 
     Blood d 2 (0.9) 2 (1.1) 0 
     Other 5 (2.2) 9 (4.8) 1 (9.1) 
Charlson comorbidity index, n (%) e    
     0 80 (35.6) 28 (14.9) 0 
     1 56 (24.9) 22 (11.7) 0 
     ≥ 2 89 (39.6) 138 (73.4) 11 (100) 
     Mean ± SD 1.5 ± 1.8 3.1 ± 2.5 5.8 ± 2.6 
Serum Cr, (Mean ± S.D.), mg/dl f 1.0 ± 0.4 1.3 ± 0.5 6.5 ± 2.2 
Serum Hgb, (Mean ± S.D.), mg/dl g 13.7 ± 0.9 11.3 ± 0.9 10.5 ± 0.7 
May not total 100% due to rounding. Cr=creatinine; Hgb= Hemoglobin. Missing values: Race (n=51), socioeconomic status index (n=204), tobacco (n=34), 
alcohol (n=102), body mass index (n=65) a Tertiles of factor score of median household income, median house rent, percentage of the population living 
below 150% of the poverty line, education index, and percent unemployed; b Current vs never; c presence of ICD-O-3 code in tumor registry data prior to 
MGUS diagnosis; d Includes multiple myeloma, leukemia, lymphoma.; e Using a modified Charlson score with 15 components; f Normal levels less than 
2mg/d; g Normal levels between 12 and 15 mg/dl 
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Table 3. Logistic regression models of the association between trajectory group and multiple myeloma.  
Trajectory group Multiple myeloma Crude OR (95% CI) Adjusted OR (95% CI) * 
     Normal Cr/Hgb 6 (3%) Ref. Ref. 
     Normal Cr/normal-lower Hgb 14 (7%) 2.94 (1.10-7.80) 5.22 (1.78-15.32) 
     High Cr/borderline Hgb 1 (9%) 3.65 (0.40-33.27) 12.28 (1.03-146.05) 
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One percent of patients with monoclonal gammopathy of undetermined 
significance (MGUS) progress to multiple myeloma per year. To evaluate the impact of 
receiving an MGUS diagnosis on healthcare utilization, we compared hospital, 
emergency room (ER), and outpatient visits between patients with and without MGUS. 
 
Methods 
A cohort of patients with MGUS identified by a recent algorithm (n=429) were 
matched on sex, age (± 2 years) and length of enrollment in the health system (-12/+6 
months), to a cohort of patients without MGUS (n=1,286). Three-time frames were 
assessed: one year before, one month before and after, and one year after diagnosis/index 
date. Multivariable conditional Poisson models were used to evaluate the magnitude of 
change of each service in patients with MGUS as compared to patients without MGUS. 
 




Half the population was female, with a mean age at diagnosis/index date of 75 
years. The majority was non-Hispanic White (MGUS:98%, non-MGUS:96%), and the 
mean Charlson comorbidity index score was higher for patients with MGUS than those 
without (2.3 versus 1.6, p-value<0.05). During the two-month period around 
diagnosis/index date, the rates of ER visits (Adjusted Incidence Rate Ratio [aIRR]:1.7, 
95% CI:1.1-2.8), hospital visits (aIRR:4.7, 95% CI:2.8-7.8) and outpatient visits 
(aIRR:2.9, 95% CI:2.6-3.2) were higher for patients with MGUS than patients without 
MGUS. In the year following MGUS diagnosis, the association was attenuated, although 
still elevated.  
 
Conclusions 
Our study suggests that MGUS diagnosis is associated with higher utilization of 









Multiple Myeloma (MM) is the second most common hematologic malignancy in 
the US and five-year survival is 54% in these patients.1–3  Monoclonal gammopathy of 
undetermined significance (MGUS) is a pre-malignant plasma cell disorder preceding the 
development of multiple myeloma.17,45,46 This premalignant condition is asymptomatic, 
however, and is typically diagnosed incidentally through blood tests.24,45,52 Patients with 
MGUS progress to multiple myeloma at a rate of approximately 1% annually,22,38,53 yet 
despite the relatively low risk of progression, patients with MGUS are regularly followed 
up for signs of progression every 6-12 months.35–37 
 
There are no screening programs available for MGUS detection, primarily due to 
a lack of treatment for MGUS and the relatively low probability of subsequent 
development of multiple myeloma.22,53,38 Understandably, patients may experience high 
levels of stress after a diagnosis of MGUS,35–37 which could result in changes in 
healthcare services utilization.68 Furthermore, associated anxiety could result from the 
emotional burden which could cause someone to disengage completely with the 
healthcare system, or inversely, try to get more frequent follow-up care to monitor the 
potential progression to multiple myeloma.38 There are multiple published MGUS 
follow-up guidelines with different recommendations, and thus follow-up care guideline 
for patients with MGUS may be variable.32  
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Quantifying the care and surveillance of patients with MGUS is of clinical 
relevance given that multiple myeloma patients with a pre-existing MGUS diagnosis 
have been shown to have a better multiple myeloma prognosis.24,52,69 In addition, 
previous studies have shown that cancer patients have better outcomes if they had greater 
utilization of primary care preceding their cancer diagnosis.40–43 Consequently, the 
elucidation of healthcare utilization patterns among MGUS patients may provide insight 
into how patients with MGUS differ clinically from patients without this diagnosis, and 
provide the first step in determining the factors that may contribute to their observed 
prolonged survival following a multiple myeloma diagnosis.39  
 
There are limited studies evaluating the impact of a MGUS diagnosis on ER, hospital and 
outpatient visits. A previous study found that the number of self-reported ER visits was 
significantly lower in participants with MGUS compared to those without, while the 
number of self-reported hospital and outpatient visits were not significantly different 
between both groups.70 The purpose of our this matched cohort study, using real-world 
data from patients seeking care at a large provider group practice in central 
Massachusetts, was to compare hospital, ER, and outpatient visits between a cohort of 
patients with MGUS and a cohort of patients without MGUS. We assessed the 
association across three time-frames: one year before diagnosis/index date, one month 
before and after diagnosis/index date, and one year after diagnosis/index date.  






This study was approved by the Institutional Review Board of the University of 
Massachusetts Medical School (UMMS). Informed consent was not required by study 
participants since this is a secondary analysis of a limited dataset derived from electronic 
health data. The data for this study were derived from the Virtual Data Warehouse 
(VDW) housed at the Meyers Primary Care Institute (MPCI), a research institute 
affiliated with the UMMS, Fallon Health, an insurer, and Reliant Medical Group (RMG), 
a community-based multispecialty provider organization. Additional data on cancer 
diagnoses were obtained from the Massachusetts Cancer Registry (1999-2016) and from 
an in-house tumor registry at RMG (2012-2018). The VDW is a standardized data 
resource which consists of electronic datasets populated with linked demographic, 
administrative, and outpatient laboratory test results, and healthcare utilization data 
(ambulatory visits and network and non-network hospital visits, including diagnoses and 
procedures) for patients receiving care at RMG from January 1, 1999 through December 
31, 2018.60  
 
Patients with MGUS 
This study includes 429 patients with MGUS who were identified through the 
application of a case-finding algorithm to the electronic health record (EHR)-based VDW 
database, previously detailed elsewhere.61 Briefly, all patients with MGUS had at least 
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two MGUS diagnosis codes within 12 months in their EHR between January 2007 and 
December 2015, plus at least one serum or urine protein electrophoresis test, one 
immunofixation test, and at least one in-office visit with an oncologist within 90 days of 
MGUS diagnosis. Patients with a diagnosis of multiple myeloma at baseline (nternational 
Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) morphology code 9732) 
or within 3 months following MGUS diagnosis were excluded.  
 
Study design 
We used a matched cohort study design. For each patient with MGUS, three 
patients without MGUS were selected from a population-based sample of the active 
patient population included in the VDW.60 Controls were matched to cases by age (±2 
years), sex, and length of enrollment in the health system (12 months before and 6 
months after index date). Patients without MGUS were enrolled in the study based on 
MGUS cases’ first date of diagnosis, which became the patients without MGUS’ index 
date. After matching was completed, one patient without MGUS was excluded because 
there was no evidence of healthcare utilization during the study period.  
 
Outcomes 
The study outcomes were the total number of ER, hospital, and outpatient visits in 
the year before (30-365 days before), the months immediately adjacent to (30 days before 
and after), and one year after (30-365 days after) MGUS diagnosis/index date. The one 
year period after a diagnosis of MGUS was selected since most guidelines recommend 
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that people return for a follow-up visit within 6-12 months after diagnosis.26–29 All ER, 
hospital and outpatient visits were extracted from EHR and claims data using Current 
Procedural Terminology (CPT) codes (Supplemental Table 1).  
 
Statistical Analysis 
Descriptive statistics were used to compare sociodemographic and clinical 
characteristics of patients according to MGUS status. Continuous variables were 
compared using t-tests, while chi-square tests were used to compare categorical variables. 
Chi-square tests were also used to describe and compare characteristics of patients with 
or without MGUS diagnosis that had at least one ER, hospital, or outpatient visit. 
Descriptive statistics were used to describe the total use of services among patients with 
and without MGUS. In addition, the mean number of ER, hospital, and outpatient visits 
incurred by patients with MGUS were compared to patients without MGUS using a t-test.  
 
We also evaluated other covariates that are known to be associated with a MGUS 
diagnosis or healthcare utilization, including sex (male/female), age at diagnosis/index 
date (continuous), race/ethnicity (non-Hispanic White vs. other race/ethnicities), tobacco 
use (never, quit/former/passive and current smoker), current alcohol use (yes/no), 
overweight/obese (>25 kg/m2; yes/no), history of cancer diagnosis at baseline (breast, 
prostate, blood, other) identigy by ICD-0-3 codes in EHR prior to MGUS diagnosis/index 
date, Charlson comorbidity index (categories: 0, 1, ≥ 2; and continuous). We used 
conditional Poisson regression, a method that has been previously used to analyze data 
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from matched cohort studies. This conditional fixed-effect modeling allows us to adjust 
for overdispersion and correlation between matched subjects. 71,72 .Crude models and 
models adjusted for charlson comorbidity index categories were used to evaluate the total 
count of each category of healthcare utilization services (ER, hospital, and  outpatient 
visits) among patients with MGUS as compared with their matched cohort of patients 
without MGUS. 71,72 
  





Sociodemographic and clinical characteristics 
Because of matching, patients with MGUS and without MGUS were similar in 
almost all sociodemographic and clinical characteristics. More than half the patients were 
men (50.6%), with a mean age at diagnosis/index date of 75 years old. The majority were 
non-Hispanic White (96.9%). However, patients with MGUS had a significantly higher 
Charlson comorbidity index (2.3) than patients without MGUS diagnosis (1.6; p-
value=0.0001) (Table 3).  
 
Emergency department visits 
A significantly higher percent of patients with MGUS had at least one emergency 
department visit one year before (21.0% vs 10.3%; p-value<0.05), 30 days before and 
after (6.3% vs 2.9%; p-value<0.05) and one year after (23.3% vs 14.4%; p-value<0.05) 
MGUS diagnosis date than patients without MGUS (Table 1). Among those patients who 
had at least one emergency department visit, there was no significant difference in the 
average count of emergency department visit by MGUS status across all time periods 
(Table 4).  
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After adjusting for Charlson comorbidity index and race, patients with MGUS 
were 55% (IRR:1.55; 95% CI: 1.24 to 1.94) more likely to have an emergency 
department visit than patients without MGUS diagnosis one year before diagnosis/index 
date. During the 30 days before/after index day patients with MGUS were 74% (IRR: 
1.74; 95% CI: 1.07 to 2.82) more likely to have an emergency department visit than 
patients without MGUS. Similar, yet slightly attenuated results were observed during the 
year after MGUS diagnosis/index date as patients with MGUS were 50% (IRR: 1.50; 
95% CI: 1.24 to 1.820 more likely to have an emergency department visit than patients 
without MGUS (Table 5).  
 
Hospital visits 
A significantly higher percent of patients with MGUS had at least one hospital 
visits one year before (14.0% vs 5.0%; p-value<0.05), 30 days before and after (4.7% vs 
1.2%; p-value<0.05) and one year after (13.5% vs 8.8%; p-value<0.05) MGUS diagnosis 
date than patients without MGUS. Among patients who had at least one hospital visits 
during the year after MGUS diagnosis/index date, the average number of hospital visits 
was slightly higher for those with MGUS than patients without MGUS (4.1 vs 3.1; p-
value = 0.001). However, no difference in the average number of hospital visits was 
observed by MGUS status before MGUS diagnosis/index date, and during the two-month 
period around diagnosis/index date (Table 4). 
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After adjusting for Charlson comorbidity index and race, patients with MGUS 
were two times (95% CI: 1.81to 2.83) more likely to have a hospital visit than patients 
without MGUS one year before diagnosis/index date. During the 30 days before/after 
index date, patients with MGUS were five times (95% CI: 2.78 to 7.87) more likely to 
have a hospital visit than patients without MGUS, while during the year after MGUS 
diagnosis/index date patients with MGUS were 67% (95% CI: 1.40 to 1.99) more likely 
to have a hospital visit than patients without MGUS (Table 5).  
 
Office or outpatient visits  
There were no significant differences in the proportion of patients who had at 
least one outpatient visit during the year before (52.7% vs 51.1%) and the year after 
(62.2% vs 59.2%) MGUS diagnosis/index date. However, more patients with MGUS had 
at least one outpatient visit 30 days before/after diagnosis/index date (54.1% vs 32.6%) 
than patients without MGUS. Among patients who had at least one outpatient visit during 
all periods evaluated, the average number of outpatient visits was slightly higher for those 
with MGUS than patients without MGUS (Table 4). 
 
After adjusting for Charlson comorbidity index and race, patients with MGUS 
were 27% (95% CI: 1.21to 1.35) more likely to have an outpatient visit than patients 
without MGUS diagnosis one year before diagnosis/index date. During the 30 days 
before/after index date, patients with MGUS were three times (95% CI: 2.59 to 3.17) 
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more likely to have an outpatient visit than patients without MGUS, while during the year 
after MGUS diagnosis/index date patients with MGUS were 49% (95% CI: 1.42 to 1.57) 
more likely to have an outpatient visit than patients without MGUS (Table 5).  
 
  





In this matched cohort study of patients seeking care at a large provider group 
practice in central Massachusetts, we examined whether a diagnosis of MGUS was 
associated with differences in ER, hospital, and outpatient visits. We compared two 
matched patient groups: one with at least two MGUS diagnosis codes in their EHR data, 
and the other without any evidence of an MGUS diagnosis. We found that patients with 
MGUS had higher rates of ER, hospital and outpatient visits one year before and after 
and during the two-month period around MGUS diagnosis/index date. However, different 
patterns of utilization were observed within the different intervals. Patients with MGUS 
had higher rates of hospital visits than patients without MGUS one year before, and 
during the one-month period around MGUS diagnosis/index date. However, a higher 
proportion of ER and outpatient visits were only higher among patients with MGUS 
during the two-month period around MGUS diagnosis/index date. 
 
After adjusting for comorbidities, patients with MGUS had higher rates of ER 
utilization, and more hospital and outpatient visits than patients without MGUS. In 
contrast, a similar study among adults 70 years or older found that patients with MGUS 
were 24% less likely to have an ER visit than patients without MGUS after 
approximately four years after diagnosis, and did not find differences between groups in 
hospital and outpatient visits.70 The conflicting results could be due to several reasons. 
First, our study used an EHR-based case-finding algorithm to identify cases with MGUS 
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using EHR and claims data, with diagnosis date defined as the first time a MGUS 
diagnostic code was identified in the EHR. In contrast, the previous study used data from 
a random sampling of community residents at North Carolina, with participants identified 
with MGUS diagnoses identified through retrospective analysis of blood samples, 
without a requirement for a clinical diagnosis.70 Second, we assessed healthcare 
utilization in three time-frames: one year before diagnosis/index date; one month before 
and one month after diagnosis/index date; and one year after diagnosis/index date. In 
contrast, patients for the previous study were asked to recall their past year healthcare 
utilization practices, four years after MGUS detection.70 We found that the healthcare 
utilization was higher in the one-month period around MGUS diagnosis/index date, while 
a decrease of healthcare utilization was evident in the year after MGUS diagnosis. These 
reasons could explain why our results differ from previous reported results.70  
 
The higher rate of ER and hospital visits among patients with MGUS in 
comparison with patients without MGUS could be explained is most likely due to 
symptoms unrelated to MGUS, because MGUS is largely asymptomatic. However in rare 
cases, patients could experience tingling, weakness or numbness related to the diseases 
process.73 In addition, patients with undiagnosed MGUS may experience unrelated 
symptoms of pain, anemia, or kidney problems,34 which could motivate those patients to 
seek urgent care, leading them to be diagnosed with MGUS. These observations could 
also explain why we observed an increase in utilization closer to MGUS diagnosis date, 
followed by a decrease during the year after diagnosis. Furthermore, the observed 
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increase in outpatient visits after diagnosis among patients with MGUS found in 
multivariable models may indicate MGUS follow-up appointments; however, we were 
not able to identify the reasons for outpatient visits in the available data.  
 
Study Strengths and Limitations 
This study has several notable strengths including the use of a matched cohort 
study design of MGUS with extensive longitudinal real-world clinical data to evaluate 
healthcare utilization before and after MGUS diagnosis. The analyses used objective data 
derived from EHRs and not self-report, which could introduce recall bias. These data 
allowed us to obtain objective measurements and longitudinal follow-up. We also 
acknowledge several limitations to this study. Since MGUS is almost always diagnosed 
incidentally, cases of MGUS were limited to those patients who sought medical care and 
may not be representative of patients with undetected MGUS. While MGUS diagnosis 
was confirmed in a sample of our population by EHR review, we were unable to review 
the EHRs of all patients, and thus some of our cases may have been false positives. In 
addition, the study population was largely non-Hispanic White patients, and future 
studies should be conducted in more diverse populations. The use of electronic health 
data has several limitations including missing variables, as data are collected as part of 
medical care and not for research purposes. In addition, within our database, we were 
unable to determine whether outpatient visits were specifically for MGUS follow up, 
which would have allowed us to further investigate MGUS-specific healthcare utilization.  
 




This study provides additional knowledge on the role of an MGUS diagnosis in 
healthcare utilization in this population. This study shows that patients with MGUS are 
more engaged with the healthcare system than patients without MGUS, particularly 
around the time of MGUS diagnosis. This pattern of care could be a potential explanation 
for how patients arrive at an MGUS diagnosis, since the condition itself is largely 
asymptomatic. In addition, greater patient engagement could explain in part why patients 
with multiple myeloma with a previous MGUS diagnosis may have better prognosis. 
24,52,69  However, future studies evaluating comorbid conditions related to MGUS 
diagnosis and follow-up are needed to understand reasons behind differences in health 
services patterns incurred by these patients. Additional research is needed to understand 
the mechanisms behind healthcare utilization and potential clinical and sociodemographic 
characteristics that may lead to improvement in the long-term overall health of patients 
with MGUS, including in larger and more diverse populations of patients with validated 
MGUS diagnoses. 
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TABLES AND FIGURES 
 
Table 3. Sociodemographic and clinical characteristics of patients according to monoclonal 
gammopathy of undetermined significance status.  








Men, n (%) 217 (50.6) 650 (50.5) 0.99 
Age at index date (Mean ± SD), year 74.9 ± 10.4 74.8 ± 10.4 0.84 
Race, n (%)    
     Non-Hispanic White 365 (97.6) 1,042 (96.2) 0.28 
     Non-Hispanic Black 6 (1.6) 19 (1.7)  
     Other 3 (0.8) 22 (2.0)  
Cancer diagnosis a    
     Breast  8 (1.9) 34 (2.6) 0.11 
     Prostate 9 (2.1) 22 (1.7)  
     Blood b 3 (0.7) 1 (0.1)  
     Other 12 (2.8) 51 (4.0)  
Charlson comorbidity index    
     0 110 (25.6) 504 (39.2) 0.0001 
     1 80 (18.6) 261 (20.3)  
     2+ 239 (40.5) 521 (40.5)  
     Mean ± SD 2.3 ± 2.3 1.6 ± 1.9 0.0001 
May not total 100% due to rounding. Missing values for race (patients with (n=55) and without 
(n=203) MGUS). a Presence of ICD-O-3 code in tumor registry data prior to MGUS 
diagnosis/index date; b Leukemia, non-Hodgkin lymphoma.  
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Table 4. Total number of participants with at least one visit (n) and average count of services per person among patients with MGUS and matched 
patients without MGUS.  
Healthcare service 
Patients with MGUS Patients without MGUSa P-valued 
n (%)b Mean ± SDc Median  
(25th-75th 
percentile) 




One year before diagnosis/index date^        
     Emergency department visits* 90 (21.0) 1.67 ± 0.97 1 (1-2) 133 (10.3) 1.68 ± 1.41 1 (1-2) 0.92 
     Hospital visits* 60 (14.0) 3.78 ± 3.11 3 (2-5) 64 (5.0) 3.33 ± 2.88 2 (2-3.5) 0.40 
     Office or outpatient visits 226 (52.7) 9.02 ± 6.60 8 (4-12) 657 (51.1) 6.19 ± 4.57 5 (3-8) <0.05 
30 days before and after diagnosis/index date^        
     Emergency department visits* 27 (6.3) 1.33 ± 1.06 1 (1-1) 38 (2.9) 1.29 ± 1.10 1 (1-1) 0.78 
     Hospital visits*  20 (4.7) 2.70 ± 1.89 2 (1.5-3.5) 15 (1.2) 2.47 ± 1.12 2 (2-3) 0.67 
     Office or outpatient visits* 232 (54.1) 3.65 ± 2.10 3 (2-5) 419 (32.6) 1.89 ± 1.23 2 (1-2) <0.05 
One year after diagnosis/index date^        
     Emergency department visits* 100 (23.3) 1.85 ± 1.76 1 (1-2) 185 (14.4) 1.78 ± 1.85 1 (1-2) 0.76 
     Hospital visits* 58 (13.5) 4.14 ± 3.39 3 (2-6) 113 (8.8) 3.11 ± 2.30 2 (2-4) <0.05 
     Office or outpatient visit 267 (62.2) 9.87 ± 6.79 8 (5-13) 761 (59.2) 6.31 ± 5.07 5 (3-8) <0.05 
a Participants were matched on age, sex and length of enrollment in the health system bn= total of patients with at least one healthcare 
service (emergency, hospital, or office/outpatient visits). c The mean, standard deviation (SD), median, and 25th – 75th percentile reported is 
among those with at least one of those services d t-test comparing means of total number of healthcare services of cases vs controls. *ᵡ2 test 
p-value < 0.05 ^Time periods are not overlapping: One year before (30-365 days before), the months immediately adjacent to (30 days 
before and after), and one year after (30-365 days after) MGUS diagnosis/index date  
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Table 5. Magnitude of change in healthcare utilization among patients with MGUS as compared with their matched cohort of patients without 
MGUS, before, during and after MGUS diagnosis/index date using conditional Poisson regression.  
Healthcare service 
One year before diagnosis/index date^ 30 days before and after diagnosis/index date^ One year after diagnosis/index date^ 
Crude Adjusted* Crude Adjusted* Crude Adjusted* 
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
Emergency department visits 2.01 (1.63-2.47) 1.55 (1.24-1.94) 2.20 (1.43-3.39) 1.74 (1.07-2.82) 1.68 (1.40-2.01) 1.50 (1.24-1.80) 
Hospital visits 3.20 (2.65-3.85) 2.23 (1.78-2.79) 4.38 (2.88-6.65) 4.76 (2.80-8.09) 2.04 (1.73-2.41) 1.65 (1.38-1.97) 
Office or outpatient visits 1.50 (1.42-1.58) 1.27 (1.20-1.34) 3.21 (2.91-3.53) 2.86 (2.59-3.17) 1.65 (1.57-1.73) 1.48 (1.41-1.55) 
*Adjusted for Charlson comorbidity index and race, participants were matched on age, sex and length of enrollment in the health system (12 months 
before and 6 months after index date).^ Time periods are not overlapping: One year before (30-365 days before), the months immediately adjacent to 
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CHAPTER IV: PATIENT AND PROVIDER-LEVEL DRIVERS OF HEALTHCARE 
UTILIZATION RELATED TO A DIAGNOSIS OF MONOCLONAL GAMMOPATHY 





Monoclonal Gammopathy of undetermined significance (MGUS) is an asymptomatic, 
incidentally diagnosed precursor to multiple myeloma, an incurable hematological cancer. We 
aimed to provide foundational knowledge about patient experiences and healthcare providers’ 
opinions and practices concerning care for MGUS patients in the United States.  
 
Methods 
We conducted semi-structured qualitative interviews to explore clinical experiences of 
patients with MGUS and to determine whether receiving an MGUS diagnosis influences 
patients’ patterns of healthcare utilization in a sample of 14 patients recruited from 
ResearchMatch and Facebook. We also conducted semi-structured qualitative interviews with 
eight healthcare providers. Interviews were analyzed using thematic analysis.  
 
Results 
We identified a total of six overarching themes around the care pathway for patients with 
MGUS. The first theme (1) was related to the process of MGUS diagnosis. Providers saw MGUS 
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as an incidental and asymptomatic condition, while patients reported having symptoms, they 
considered to be related to MGUS. Three themes focused on the meaning of an MGUS 
diagnosis, relating to: (2) providers’ explanation, (3) patients’ understanding, and (4) the impact 
of the diagnosis. Overall, patients have a basic understanding of MGUS. However, some patients 
feel anxiety around the diagnosis, which may affect other aspects of their lives. The fifth (5) 
theme was related to follow-up/management. We found that patients primarily see hematologists 
for follow-up care; non-hematologist providers report having less specific knowledge about 
MGUS. The last theme (6) was related to factors influencing healthcare utilization. We found the 
most influential factors to be age, disease severity, and insurance/cost.  
 
Conclusion 
Our findings suggest that some patients with MGUS may need psychosocial support 
services to help process their diagnosis with a premalignant condition. In addition, we identified 
gaps in knowledge around caring for MGUS patients among non-hematologist providers, and 
variation in MGUS follow-up practices. Finally, the factors identified to influence care for 
patients with MGUS are similar to factors influencing care for other chronic conditions. 
 





Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant 
condition characterized by elevated amounts of monoclonal protein (M-protein) present in the 
blood. MGUS is diagnosed more often in older adults and in men; however, cases are mostly 
asymptomatic and almost always diagnosed incidentally when patients seek care for other 
conditions.24,45,52 It is estimated that nearly 3% of adults over 50 years old may have clinical 
evidence of MGUS,30,48–51,74 yet the vast majority of these individuals remain undiagnosed. 
However, patients with MGUS can progress to more severe diseases, including the incurable 
hematological cancer multiple myeloma (MM), at a rate of approximately 1% per year.22,53 75   
 
Previous studies have shown that patients with MGUS or smoldering myeloma, an 
intermediate condition between MGUS and multiple myeloma, exhibit similar psychological 
distress as patients with multiple myeloma.76 A recent qualitative study from Ireland describes 
the poor psychological experiences that patients with MGUS endured during diagnosis and 
follow-up appointments due to uncertainty about potential progression to multiple myeloma.77 
Patients also reported experiencing isolation, poor information-provision and increased 
uncertainty after MGUS diagnosis.  
 
Patients with MGUS experience frequent follow-up clinical visits in intervals ranging 
from three months to two years. There are four international clinical practice guidelines for 
MGUS, all based on expert consensus, yet their recommendations vary widely.26–29 In the United 
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States (US), MGUS clinical surveillance practice patterns vary by sociodemographic 
characteristics; older patients are more closely followed than younger adults.32 Geographic 
variation in follow-up patterns has also been observed, with patients in the Northeastern US 
followed-up less frequently than patients from any other US region.32 In addition, the follow-up 
care for approximately half of patients with MGUS from a retrospective claims data analysis 
using the OptumLabs Data Warehouse diagnosed in 2013 lacked concordance with any of the 
existing recommended clinical practice guidelines.32,33 Patients with multiple myeloma preceded 
by a known MGUS diagnosis have been observed to have better long-term survival than multiple 
myeloma patients without this prior diagnosis,24,52,69 though mechanisms remain unclear.38,52,53 
The primary goal of this study was to understand the perspectives and experiences of patients 
with MGUS as well as the providers who diagnose and care for them. We also explored patient- 
and provider-level drivers behind patterns of healthcare services utilization.  
  






We conducted semi-structured one-on-one interviews with patients who had been 
diagnosed with MGUS to gain insight into their experiences and the factors that might influence 
their healthcare utilization practices before and after receiving an MGUS diagnosis. In addition, 
we conducted one-on-one semi-structured interviews with providers to understand the typical 
processes leading to an MGUS diagnosis and to explore potential provider-level drivers of health 
service utilization in addressing MGUS. All interviews were conducted through secure phone 
calls and recorded. This study was approved by the University of Massachusetts Medical School 
Institutional Review Board and all participants gave oral informed consent to participate.  
 
Study Participants and Settings 
Patients with MGUS: Patients were recruited from MGUS-related support groups on 
Facebook and through the ResearchMatch database.78 ResearchMatch and Facebook have 
previously been used to recruit patients for qualitative studies and studies of healthcare decision 
making.78,79 All interested participants with MGUS were provided with a fact sheet describing 
the study. Inclusion criteria included a self-reported diagnosis of MGUS, aged between 18-80 
years, and ability to speak English or Spanish, and ability to provide oral, informed consent 
 
Providers: Healthcare providers were identified through the investigators’ (MC, ME, 
KM) professional networks of healthcare providers at the University of Massachusetts Medical 
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School and Reliant Medical Group, both located in central Massachusetts. Inclusion criteria 
included healthcare providers who may treat patients with an MGUS diagnosis including but not 
limited to those in the fields of primary care, hematology/oncology, and geriatrics. Provider 
types included physicians, nurse practitioners, and physician assistants.  
 
Interview content 
Interviewees were asked a series of open-ended questions. An experienced qualitative 
researcher helped to develop and revise interview guides (KM). We collected information on 
sociodemographic characteristics for all participants, including age, gender, race/ethnicity, years 
in practice and specialty (providers only), and state of residence (patients only). We gathered 
information from patient participants about their experiences with their MGUS diagnosis and 
perceptions of how this diagnosis has influenced their care. Among provider participants, we 
solicited their perspectives on why patients may be more likely or less likely to obtain specific 
health services (Interview guides). 
 
Qualitative thematic analysis 
All interviews were transcribed and de-identified by the primary study investigator (MC). 
The coding process began with an unstructured read of the transcripts and familiarization with 
the data. After an initial review of the transcripts, we generated a preliminary list of codes.80,81 
The preliminary coding scheme was developed by the primary investigator, and reviewed by an 
experienced qualitative researcher (KM) and a cancer epidemiologist (ME). The preliminary 
coding scheme was applied to a subset of transcripts by all three investigators who then met to 
discuss coding, generate new codes as needed and refine code definitions. The primary 
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investigator applied codes to all the interviews (MC) and a second team member reviewed for 
accuracy (KM, ME). Memos of decisions were logged at each step of the planned coding 
process; team members met to review and discuss disagreements and modification of definitions. 
After all interviews were coded and collated, we reviewed coded responses and identified themes 
and subthemes. Patient and provider interviews were analyzed separately, and corresponding 
themes were compared (e.g., providers’ views on how patients understand the MGUS diagnosis 
versus patients’ descriptions of how they would explain the diagnosis).  
 
  





Characteristics of the participants  
A total of eight provider participants were interviewed; of those, five were female, four 
were non-Hispanic White, four were hematologists, four were non-hematologist providers, four 
had more than three years of medical practice, and four treat more than ten patients with MGUS 
in a year. All provider participants were currently practicing in Massachusetts (Table 6). A total 
of 14 patient participants with MGUS were interviewed; of those 10 (71.4%) were female, 11 
(79.6%) were 70 years old or less, 10 (71.4%) were non-Hispanic White, and eight (57.1%) were 
living in the southeastern US. All patient participants had a bachelor’s degree or higher, eight 
(57.1%) had lived for six or more years with a MGUS diagnosis, and 10 (71.4%) reported to 
have good or very good overall health. Patients with MGUS in this study reported having several 
comorbid conditions, including musculoskeletal diseases (e.g., arthritis, bone pain; N=7) (Table 
7). 
 
Summary of themes 
We identified a total six overarching themes among patient and provider participants that 
map onto the MGUS care pathway from diagnosis through follow-up. These themes include (1) 
process to MGUS diagnosis; (2) providers explanation of MGUS; (3) patients’ understanding of 
MGUS; (4) impact of MGUS diagnosis; (5) follow-up/management; and (6) factors influencing 
healthcare utilization (Figure 2). These themes are described in detail below. 




1. Process of MGUS diagnosis: This theme included the process of clinical evaluation that 
led provider participants to an MGUS diagnosis and affected patient participants’ 
experiences in healthcare encounters leading up to MGUS diagnosis.  
 
Circumstances leading to providers to evaluate for a possible MGUS diagnosis: Provider 
participants reported that patients with MGUS are often incidentally diagnosed while being 
evaluated for another acute or chronic condition, though some diagnoses were found during 
routine lab workups.  
 
Patient participants' experiences during MGUS diagnosis: In contrast to provider 
participant reports, six patient participants reported experiencing mostly nonspecific symptoms 
that led to the MGUS diagnosis including rash, itch, tingling, severe bone pain, fatigue and skin 
lesions. Patient participants reported a variety of experiences in receiving MGUS diagnosis. Five 
patient participants described empathetic providers who actively sought to identify (i.e., 
diagnose) the problem, took time to explain the diagnosis, and communicated with other 
providers on behalf of the patient. In contrast, two patient participants described physicians who 
they felt did not prioritize MGUS due to other concerns in their care. In addition, seven patient 
participants believed their provider did not have sufficient knowledge of MGUS, and so actively 
sought out more knowledgeable providers. 
“The person who diagnosed me with it didn't really know anything and he was like, at this point, 
all I can do is refer you to someone else and then you have to wait…then the person that I got 
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was more concerned about other issues. And so that took me a couple of years to find somebody 
that was specifically looking at [MGUS].” (Female, 5 years with MGUS) 
 
2. How providers explained MGUS to patients: This theme includes how provider 
participants explained the MGUS diagnosis to their patients and what they should expect. 
We also included the challenges to explaining MGUS to patients that provider 
participants reported during this process in this theme.  
 
Providers’ explanations of MGUS: Provider participants’ reports of how they explain MGUS to 
their patients included two aspects: a medical description (e.g., “a protein abnormally elevated”) 
and reassurance of the common and usually non-harmful nature of the diagnosis, e.g., “common 
finding as people gets older”). Patient participants’ reports of their conversations with their 
providers were consistent with these findings.  
 
Providers’ explanations about what patients could expect after the diagnosis: Provider 
participants also reported that they gave patients information about what to expect with this 
diagnosis, including that: (1) MGUS has a risk of progression to multiple myeloma if M-protein 
rises; (2) elevation of M-protein could affect organ function (anemia, renal failure, high calcium, 
etc.); (3) MGUS is a chronic condition that needs close monitoring and, while there is no need to 
be concerned right now, follow up with a blood specialist is necessary to look for signs and 
symptoms of progression. Patient participants’ reports of their conversations with their providers 
were consistent with these findings.  
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Challenges in explaining MGUS to patients: In general, provider participants reported that they 
explained MGUS using simple language for all patients, regardless of literacy level or other 
factors. Three provider participants noted that MGUS is a condition that is difficult to explain. 
However, one provider participant mentioned they modify their description of MGUS based on 
perceived patient understanding, and two provider participants indicated the challenges of 
explaining MGUS to non-English speaking patients using an interpreter.  
“I think the explanation so much doesn't change. Sometimes with the interpreter use, I stick to 
my same kind of language, but I'm not really sure what the interpreter is saying. Like, how do 
they say abnormal protein? You know what I mean? And how do the patients perceive it? It can 
be almost impossible for me to know, the medical interpreters are qualified in translating 
medical terms. I'm hoping that they they're able to convey exactly what I have in mind.” 
(Hematologist) 
 
3. Patient participants understanding of an MGUS diagnosis: This theme includes 
patient participants’ definition and understanding of the MGUS diagnosis and sources of 
information patients have used to find more information about MGUS.  
Patient participants’ definitions: Twelve patient participants were able offer an explanation of 
MGUS using definitions more ambiguous compared to those reported by providers, for example:  
“something funny in my blood that didn't cause any problem but can become something serious” 
(Female, 16 years with MGUS) 
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“The best way I can explain it is that they don't know for sure. That's the reason it says unknown 
significance is not there for sure. The best way I can say if I was gambling, I would gamble at the 
fact that I have the possibility based upon my blood work says that I am more likely to have a 
lymphoma or something like that than the average person that does not have this in their genetic 
blood.” (Female, 15 years with MGUS). 
However, two patient participants reported they do not understand MGUS and hoped one day 
they can learn more about it.  
Sources of information: All patient participants in this study used the internet to access 
information about MGUS, referring to medical journals and social media sites like Facebook. 
Social media, in particular, was helpful for some patient participants to share information and get 
recommendations to help with specific disease-related symptoms. One patient participant said:  
“I am on Facebook, I've been talking with, … texting or messaging, different people who have 
MGUS and, definitely sharing information” (Female, 3 months with MGUS) 
One provider participant noted that patients have the potential to access unreliable information 
via the internet and that they may hear information from friends and family and then call the 
physician to clarify. 
 
4. Impact of an MGUS diagnosis: This theme includes provider participants’ perspective 
on patients’ responses as well as patient participants’ reported emotional response and 
actions taken after the diagnosis.  
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Provider participants’ perspectives: Provider participants acknowledged that some patients may 
experience anxiety associated with this diagnosis, similar to other pre-cancerous conditions. Two 
provider participants reported offering reading materials or further discussion to clarify what to 
expect with an MGUS diagnosis when they perceive that a patient feels nervous or anxious. 
Provider participants mentioned the importance of reassuring patients, and that follow-up and 
subsequent healthcare utilization could be influenced by the patient’s reaction. Provider 
participants also reported that the need to visit a hematology-oncology department could be 
inherently stressful for some patients and make them worried about having cancer. 
Patient participants’ feelings or emotional responses: Patient participants reported varied 
responses to getting an MGUS diagnosis. Some reported relief after finding out they had MGUS 
and not something more serious like multiple myeloma or amyloidosis. One said:  
“I mean having MGUS seems like the better alternative to any other type of disease that could 
come from it”. (Female, 3 months with MGUS) 
Three patient participants reported having a neutral response, such as:  
“I just feel fortunate that I’m able to continue on and realize that I have to live with it and take 
whatever comes.” (Male, 6 years with MGUS)  
Other patient participants found the diagnosis mentally draining and reported that they were 
constantly thinking about it after the diagnosis:  
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“I think anytime you get a diagnosis like that, you have anxiety. … and when you have children, 
especially you worry about your own mortality and being alive to see them, …, grow up and do 
things.” (Female, 10 years with MGUS)   
Finally, some patient participants recognized their emotions fluctuated, particularly when time 
came close to follow-up visits. One said:  
“The biggest impact that I’ve had is when it’s time for my appointments, where I, … go for the 
blood tests about a week in advance …when we get there to discuss the test results, then the 
biggest impact has been I get a little depressed”. (Female, 5 years with MGUS) 
Actions taken by patient participants: Some patient participants reported taking actions after 
getting the diagnosis, including making changes to their insurance policy or taking herbal 
remedies. One patient participant was keeping a diary of skin changes while another patient 
reported getting married earlier than planned.  
 
5. Follow-up and/or management plan: This theme refers to the follow-up practices 
described among patient and provider participants in this study, including used of other 
healthcare services, and patient participants experiences during MGUS follow-up. Also, 
this theme identifies the need to establish the importance of MGUS follow-up 
MGUS follow-up practices: After an MGUS diagnosis, two patient participants were followed 
by their primary care physician while all others were followed by a hematologist. Providers 
reported variability in the specialty of providers responsible for patient follow-up with MGUS, 
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with non-hematologist mostly responsible for long-term surveillance. In general, hematologists 
saw the patient only to confirm the MGUS diagnosis, then referred them back to the primary care 
physician. However, two hematologist provider participants mentioned that they follow patients 
with MGUS if the patient needs more reassurance or if the primary care physician does not feel 
comfortable managing these patients. One provider participant mentioned patients with MGUS 
are followed by multiple providers, and two other provider participants mentioned the primary 
care physician and hematologist collaboratively manage patient’s care. One provider participant 
highlighted the need for increased knowledge about MGUS among primary care physicians:  
“So the one thing about MGUS, it's kind of like an incidental finding... sometimes we get more of 
these patients that we should be getting. What would really be helpful is education of primary 
care physicians of what it means and when they need to worry about that.” (Hematologist) 
In contrast to provider participant reports, 12 patient participants reported being followed-up by a 
hematologist rather than a primary care physician, as the latter were not familiar with the 
condition. 
The frequency of clinical follow-up done by the provider participants was variable, ranging from 
every three months to every two years. Some provider participants indicated the frequency of 
follow-up depends on laboratory test results and patient risk level. Provider participants noted the 
lack of clear follow-up guidelines for following patient participants with MGUS:  
“So we see them, … every six months, sometimes every 12 months, … there is no real guidelines, 
different organization or different country has its own set of rules. …there's such a variability 
into how often you need to check them.” (Hematologist) 
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Even though most standard surveillance tests (e.g., serum protein electrophoresis) were 
mentioned by almost all the providers, differences in the frequency of testing were reported. For 
example, immunofixation tests may not be ordered routinely because a positive result won’t 
change over time:  
“I don't routinely do immunofixation because immunofixation has already been done and it 
should be positive going forward.” (Hematologist) 
Mental health services and other services: Most provider participants reported that there are no 
specific health services needed by patients with MGUS. However, if patients are experiencing 
specific symptoms (e.g., neuropathy), they may receive relevant treatment (physical therapy). 
Provider participants also mentioned that in general patients with MGUS generally do not need 
referrals to mental health services. Oncologist provider participants expressed confidence in their 
ability to reassure patients, provide information, and communicate with family members. 
However, one provider participant reported that while patients with MGUS may not need a 
referral to mental health services, they may need such a referral later if their condition progresses 
to multiple myeloma.  
Patient participants may feel differently about this, as one patient mentioned the 
importance of checking on patients’ emotional wellbeing:  
“As much, and as passionate as physicians are… there is not often the time to say, can 
we do a little check-in? How are you doing emotionally and intellectually so that we can 
understand that part to treat the whole person instead of just the condition.” (Female, 14 years 
with MGUS) 
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Patient participants' experiences during MGUS follow-up: Patient participants reported 
difficulty finding a provider with adequately familiarity with MGUS. One patient participant 
traveled out of state each year to continue follow-up with a provider comfortable with MGUS. In 
addition, one patient participant highlighted how providers play an important role in the follow-
up of patients:  
“The people who treat you make an enormous difference in how this goes”. (Male, 10 years with 
MGUS) 
Follow-up importance: Patient participants reported the need to understand the importance of 
MGUS follow-up:  
“You really have to have a mental construct about … why would you take time out of your day to 
do this thing? it's not something that's causing you any problems, why should you do anything?” 
(Female, 16 years with MGUS) 
One patient, who developed multiple myeloma after 16 years with MGUS described how 
knowing the importance of follow-up would be helpful:  
“What difference does it make? … what will happen if … it emerges into illness, I will get 
treated, you know, and they would say, well, if we catch it a little earlier, it will be a little 
better.” (Female, 16 years with MGUS) 
6. Factors influencing healthcare utilization: All providers participants indicated they 
continue the same management plan and generally do not alter the care of MGUS 
patients. One provider participant mentioned that the factors influencing healthcare 
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utilization after an MGUS diagnosis are no different than for other chronic conditions. 
However, patient and provider participants both reported a few factors that can influence 
healthcare utilization. Some of those were: 
Symptoms/comorbidities: Provider participants mentioned that any signs of progression, such as 
neuropathy or renal insufficiency, and/or patients with high risk MGUS (IgM subtype) will result 
in more aggressive follow-up, where a short life expectancy or advanced comorbid disease result 
in less aggressive MGUS follow-up. Provider participants may change MGUS follow-up 
practices if patients have comorbidities. In general, patients with poorer overall health were less 
likely to prioritize monitoring for MGUS progression.  
Patient age: Provider participants varied in whether they modified their follow up care based on 
patient age. Some providers indicated that age influenced clinical follow-up patterns, with older 
patients receiving less intense follow-up than younger patients. In contrast, other provider 
participants indicated that MGUS follow-up is not age-dependent while others still expressed 
conflicting thoughts on the influence of age.  
In addition, one patient participant commented that she felt she was getting less attention, given 
her young age: 
“It tends to get kind of pushed off.... You're young. You don't really need to worry about medical 
issues yet.” (Female, 5 years with MGUS) 
Other barriers/factors influencing healthcare utilization: Other factors influencing healthcare 
utilization that were identified by patient and provider participants included: providers’ lack of 
knowledge of MGUS can lead to unnecessary referrals; patients’ interest in having more frequent 
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follow-up; patient feelings, like anxiety/worry; family history of multiple myeloma; 
transportation concerns; emotional and physical burden; COVID-19 related concerns; language 
barriers; insurance/cost; distance from home to healthcare facilities; the difficulties and 
monotony of enduring long term follow-up; and waiting time for lab results. One patient 
participant said: 
“I certainly spend a lot more money on copays and certain things that aren't covered. And it 
does put financial stress” (Male, 6 months with MGUS) 
  





This study provides insights into patients and providers' experiences with MGUS and 
patterns of MGUS follow-up healthcare utilization. The providers and patients who participated 
in this qualitative study expressed emphasized the importance of different aspects of follow-up 
care. We described patients' experiences with an MGUS diagnosis and follow-up care to 
understand how they view an MGUS diagnosis and integrated it into regular care that they 
sought out. We identified these themes: (1) process to MGUS diagnosis; (2) providers 
explanation of MGUS; (3) patients’ understanding of MGUS; (4) impact of MGUS diagnosis; 
(5) follow-up/management; and (6) factors influencing healthcare utilization. 
 
MGUS diagnosis, follow-up and management  
Studies have shown that cancer patients have better outcomes if they have greater 
utilization of primary care before diagnosis.40–43 Primary care generally plays a central role in the 
delivery of healthcare delivery system and serves as the basis for building a strong healthcare 
system that ensures better health outcomes and health equity.82 Patients with MGUS seem to 
have frequent follow-up visits to monitor their disease,25 which may be a direct result of 
established guidelines and recommendations. However, in our study we found that the majority 
of patients are followed by a hematologist-oncologist, due to the lack of MGUS knowledge 
among primary care physicians. This gap in primary physician knowledge could delay a newly 
diagnosed patient’s referral to hematologist-oncologist or incur in additional specialty referrals 
as a patient rules out other conditions.  
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Previous studies have observed that patients with multiple myeloma preceded by a known 
MGUS diagnosis have better long-term survival than multiple myeloma patients without this 
prior diagnosis,24,52,69 though the reasons for this remain unclear.52,53,75 Investigating healthcare 
utilization by patients with MGUS may provide insight into the mechanisms behind the 
improved survival of multiple myeloma patients with this preceding diagnosis.39,83 A previous 
study that evaluated the follow-up practices of MGUS in the US found that MGUS follow-up 
practice patterns varied geographically and demographically and were frequently discordant with 
guideline recommendations. 25 
 
A recent study from a cohort of patients with MGUS living in southeastern Minnesota 
and followed up at Mayo Clinic, examined the indications for monoclonal protein testing, 
subsequent diagnoses made, and follow-up practice patterns.84 They found monoclonal protein 
testing is commonly performed for signs and symptoms not typically associated with 
lymphoplasmacytic malignancies. In addition, there was significant variation in MGUS follow-
up between hematologists and non-hematologists that is not based on risk factors or clinical 
practice guidelines.84 Similar to our study, providers and patients reported variations in follow-up 
practices. There is the need for clear and consistent recommendations for MGUS surveillance to 
reduce the potential for miscommunication and ensure adequate follow-up for all MGUS 
patients. In particular, patients in our study indicated the importance of recognizing the benefit of 
continuous, long-term follow-up for a condition that does not often cause any urgent medical 
concerns.  
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Providers’ explanation and patients understanding of MGUS  
A previous study has found that physicians describe MGUS to their patients using simple 
terminology such as “abnormal protein” and using analogies that the patient was more likely to 
be familiar with, such as comparing a paraprotein to the finding of a mole or lump.44 Also, 
education level, age and cognitive ability are found to be important factors in deciding how and 
whether information was relayed to patients.44 However in our study, providers indicated that 
they generally give the same definition to all patients. Also, providers recognize that MGUS is 
difficult to explain, and it is challenging to explain the condition to those patients who need 
interpretive services.  
A previous study that investigated patients’ knowledge and understanding of 
nonmalignant blood disorders found that patients may understate the significance of such 
conditions.37 In contrast, almost all patient participants in our study seemed to understand 
MGUS, although a few patients recognized that they do not have a good understanding of the 
condition. 
 
Impact of MGUS diagnosis 
We found that providers recognized that patients with MGUS could present with anxiety 
associated with MGUS diagnosis and long-term follow-up. However, providers also expressed 
confidence that they were able to reassure patients, educate them, and communicate with family 
members, and were not likely to refer patients to mental health resources. Patients expressed 
different emotions after an MGUS diagnosis, including anxiety, which may affect other aspects 
of their lives. These results suggest an unmet need for providers to evaluate the emotional well-
being of MGUS patients, and possibly make mental health resources more available. These 
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observations are similar to a qualitative study of patients with MGUS in Ireland, which found 
that an MGUS diagnosis can result in isolation and increased uncertainty.77  
 
Study Strengths and Limitations 
This study had several strengths including the evaluation of both patient and providers’ 
perspectives of MGUS. However, we recognize this study does have several limitations. First, 
we recruited a relatively small number of patients, and the use of ResearchMatch and/or social 
media for recruitment may limit the generalizability of the results, as our participants may be 
more educated or engaged than typical patients. In addition, our patient participants were mainly 
non-Hispanic White patients and highly educated. The patients who were interviewed were 
unlikely to have been cared for by the providers in the study; thus, future research exploring 
differences in perceptions within patient-provider dyads would be useful. Finally, given the small 
number of providers interviewed we were unable to make comparisons across specialties.  
 
Conclusion 
Future studies should explore strategies for increasing primary care providers’ knowledge 
and self-efficacy in MGUS management, as was suggested by patients’ reports of difficulty 
finding physicians who could offer adequate follow-up care. These findings also suggest that 
providers should screen for and address mental health concerns more often among patients with 
MGUS. Providers should be aware that an MGUS diagnosis may negatively impact a patient’s 
mental health and should be prepared to offer adequate mental health referrals if needed. In 
summary, these findings are an important first step in understanding patients’ experiences with 
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MGUS, as well as patient and provider-level drivers of healthcare utilization related to a 
diagnosis of MGUS. 
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TABLES AND FIGURES 
Figure 2. Overarching themes identified among patients and providers around healthcare utilization before, during, and after diagnosis 
of monoclonal gammopathy of undetermined significance (MGUS) 
 
Overarching themes – gray ovals 
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Table 6. Self-reported characteristics of US medical providers who care for patients diagnosed with 







Gender   
     Male 3 37.5 
     Female 5 62.5 
Race/ethnicity   
     Non-Hispanic White 4 50.0 
     Asian/Indian 4 50.0 
Type of provider   
     Non-hematologist 4 50.0 
     Hematologist 4 50.0 
Years of practice    
       2 4 50.0 
      3-10 2 25.0 
       11 2 25.0 
Practice setting   
     Private practice 2 25.0 
     Hospital 6 75.0 
Number of patients with MGUS seen per 
year 
  
      10 4 25.0 
     11-20 2 25.0 
      21 2 25.0 
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Table 7. Self-reported characteristics of patients diagnosed with monoclonal gammopathy of 
undetermined significance (MGUS)  
Characteristics  
Patients with MGUS 
N=14 
N (%) 
Gender   
     Male 4 28.6 
     Female 10 71.4 
Age   
     60 3 21.4 
     61-70 8 57.1 
     71 3 21.4 
Race/ethnicity   
     Non-Hispanic White 10 71.4 
     Non-Hispanic Black 2 14.3 
     Multi-racial 2 14.3 
Region of residence   
     Northeast (MA, NY) 2 14.3 
     Southeast (NC, FL, VA, MS, KY, TN) 8 57.1 
     Midwest (IL, IN) 3 21.4 
     West (CA) 1 7.1 
Level of education   
     Doctoral degree 3 21.4 
     Master’s degree 4 28.6 
     Bachelor’s degree 7 50.0 
Any family history of cancer 11 78.6 
Years since MGUS diagnosis   
      1 2 14.3 
     2-5 4 28.6 
     6-10 3 21.4 
      11 5 35.7 
Comorbid conditions at time of interview*   
     Neuropathy 1 7.1 
     Diabetes 2 14.3 
     Kidney disease 2 14.3 
     Hypertension 4 28.6 
     Musculoskeletal disorders 7 50.0 
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CHAPTER V: DISCUSSION AND CONCLUSIONS 
 
SUMMARY OF FINDINGS 
 
The main goal of this dissertation was to provide a foundation of knowledge for 
future studies of healthcare utilization among patients with MGUS. Specifically, this 
research was designed to assess factors contributing to healthcare utilization in a 
population diagnosed with a prevalent yet understudied premalignant condition, with the 
intention of laying a foundation for future studies that will help elucidate potential targets 
to improve the long-term health and survival of patients with MGUS.  
 
Using data from a community-based provider group in central Massachusetts, the 
first study aimed to describe relevant MGUS biomarkers’ (creatinine and hemoglobin 
laboratory values) trajectories during a period of three years after MGUS diagnosis, as 
these are monitored for disease progression. We identified three distinct groups of 
patients with MGUS sharing similar trajectories of creatinine and hemoglobin laboratory 
values over the three years following diagnosis. Slightly more than half of the patients 
with MGUS had a normal creatinine and hemoglobin trajectory, while 44.3% of patients 
had a trajectory with lower hemoglobin levels that remained within the range of normal. 
Lastly, a smaller group of patients (2.6%) had a trajectory characterized by high 
creatinine and borderline low hemoglobin levels. We found that few patients in our study 
population transitioned to multiple myeloma over the course of our study.  




Our second aim consisted of a matched cohort analysis of patients seeking care 
at a large provider group in central Massachusetts. We examined whether a diagnosis of 
MGUS was associated with differences in ER, hospital, and outpatient visits compared to 
patients without an MGUS diagnosis. We found that patients with MGUS had higher 
rates of ER, hospital, and outpatient visits one year before and after, as well as during the 
two-month period around MGUS diagnosis/index date. However, different patterns of 
utilization were observed between the different time intervals. Patients with MGUS had 
higher rates of hospital visits than patients without MGUS one year before, and during 
the two-month period around MGUS diagnosis/index date. However, the rates of ER and 
outpatient visits were higher than patients without MGUS during the two-month period 
around the MGUS diagnosis/index date. 
 
The final study aim explored the patient- and provider-level drivers of healthcare 
utilization in patients with MGUS. The providers and patients who participated in this 
qualitative study expressed varied opinions regarding MGUS follow-up and healthcare 
utilization. We described patients' experiences with an MGUS diagnosis and follow up to 
understand how patients view their MGUS diagnosis in context of their overall care. 
Overall, patients demonstrated a basic understanding of MGUS and its implications. 
However, some patients reported feeling anxiety associated with an MGUS diagnosis, 
which may affect other aspects of their lives. In contrast, providers saw MGUS as an 
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asymptomatic and incidental diagnosis that does not cause any trouble and indicated that 
patients did not need additional healthcare services (e.g., mental health referrals). Finally, 
providers viewed the factors influencing MGUS management strategy are generally no 
different than those that affect the management of other chronic conditions. Furthermore, 
we found that primary care providers may require additional and specific training on 
MGUS to ensure adequate follow-up care of these patients.  
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STRENGTHS AND LIMITATIONS 
 
The research conducted for this dissertation has several notable strengths. We 
conducted a population-based analysis of the multiple myeloma precursor MGUS using 
both quantitative and qualitative methods. The findings reported in the three studies 
presented here will add knowledge to the relatively scarce literature on the impact of 
receiving an MGUS diagnosis on healthcare utilization. This study is the first to evaluate 
healthcare utilization pre- and post-MGUS diagnosis, as well as compared to a population 
without MGUS (matched cohort design), in a community-based sample of patients with 
MGUS with longitudinal electronic health record data. For the first two studies of this 
dissertation, we used a database of patients with MGUS diagnosed between 2007 to 2015 
who were identified with an innovative algorithm based on electronic health data, with a 
portion of cases validated through EHR review.85 We used a rigorous advanced statistical 
method (group-based trajectory modeling) to conduct an innovative analysis to 
disentangle how levels of two common clinical biomarkers evolve over time prior to and 
following the diagnosis of MGUS and identified distinct groups of patients based on 
these clinical markers. Finally, this study was the first to evaluate the drivers of 
healthcare utilization in patients with MGUS at both the patient and provider levels using 
qualitative methods.  
 
We also recognize that this work had several limitations. Because the majority of 
MGUS cases are undiagnosed, the study findings are generalizable to all patients with 
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diagnosed MGUS, which by definition requires access to medical care. Since the 
algorithm used to detect patients with MGUS was developed in the setting of a healthcare 
delivery system, the findings for the first two analyses may be limited to an insured 
population. Electronic health data offer several challenges including missing data, 
missing variables, and variability in the amount of data available in the EHR per patient, 
including MGUS-related surveillance testing. Advanced analytic approaches (e.g., 
multiple imputations for missing data) were applied to address these challenges. We 
acknowledge that we could not completely compensate for data missing in patients’ EHR 
(e.g., smoking status, alcohol used, and body mass index). Regarding the qualitative 
study, we performed a relatively small number of interviews with patients and providers, 
and there may still themes left to be explored. However, this approach should be 
sufficient to learn about the range of ideas and to inform new different hypotheses to 
explore in future quantitative and mixed methods studies. Also, the patients who were 
interviewed may not have been cared for by the providers who participated. Future 
studies may investigate patient-provider dyads. Finally, given the small number of 
providers interviewed, we were unable to make comparisons across specialties. 
 
  





The work produced from this dissertation has provided foundational information 
on healthcare utilization among patients with MGUS. However, future research is still 
needed. There are several areas that future studies should examine in relation to 
biomarker trajectories of patients with MGUS. First, additional laboratory value 
trajectories including M-protein and calcium levels should be examined. The inclusion of 
additional laboratory results will provide a more comprehensive picture of patients with 
MGUS and their pathway towards potential progression to multiple myeloma. Second, 
future studies should include diverse populations, especially those known to be at a 
higher risk of multiple myeloma, such as African Americans to determine if biomarker 
trajectories are similar in other populations, and to increase generalizability of findings. It 
is important to note that our study sought only to characterize MGUS patients based on 
biomarker trajectory, and not to predict risk of progression to multiple myeloma. 
Additional methods must be developed to further apply identified trajectories to risk 
prediction.  
Future studies evaluating comorbid conditions related to MGUS diagnosis and 
follow-up are needed to understand the differences in healthcare patterns observed among 
patients with MGUS, since the differences observed could be related to other conditions 
and not due to MGUS diagnosis. Additional research is also needed to understand the 
mechanisms behind healthcare utilization in patients with MGUS, including in larger and 
more diverse populations of patients with validated MGUS diagnoses. Given the 
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limitation that our participants were mainly identify as non-Hispanic White, our results 
may lack generalizability. Future work in this field should also incorporate a greater 
number of diverse geographical locations given known geographic variation in follow-up 
practices in the US. Future studies may explore additional healthcare services, such as 
preventive health behaviors, that could help us better understand the overall health and 
care patterns of patients with MGUS.  
 
Lastly, results from our qualitative analysis of patients with MGUS suggest that 
future studies must evaluate the need of patients with MGUS to be monitored by primary 
care physicians with adequate knowledge for emerging signs of multiple myeloma 
progression. Lack of adequate follow-up among patients with MGUS could result in a 
greater risk of MGUS patients having avoidable complications. Our study identified 
potential gaps in training as primary care providers may not be adequately informed on 
care for patients with MGUS. As such, future studies may develop educational materials 
not only for primary care providers, but also for newly diagnosed MGUS patients to 
inform themselves on the disease. If primary care providers lack adequate knowledge 
around the importance of regular surveillance or possible complications from MGUS, 
patient symptoms may be inadequately evaluated.  
 
  





This dissertation has evaluated the influence of receiving a diagnosis for the 
precancerous condition MGUS in relation to healthcare utilization practices. MGUS is 
the precursor of multiple myeloma, one of the most common forms of hematological 
cancer, with five-year survival rate of just 54%86 despite recent improvements in 
treatment. MGUS and multiple myeloma are more common among adults aged 50 years 
and older and people of African descent who have a 2-fold higher risk than non-Hispanic 
White patients. The goal of this dissertation was to shed light on this understudied 
premalignant condition and its impact on healthcare utilization, as well as characterize 
subgroups of patients based on commonly measured biomarkers and gain a better 
understanding of patient- and provider-level drivers of health behaviors in this 
population. Future research should further investigate how the group trajectories 
identified in this study may be related to the risk of progression to multiple myeloma, 
including evaluating the addition of biomarkers such as M-protein levels. In addition, we 
suggest that an MGUS diagnosis is associated with higher utilization of ER, hospital, and 
outpatient visits, especially during the months surrounding the diagnosis date. Our study 
suggests the need for additional psychosocial support services for patients with MGUS 
who may experience anxiety as a result of the diagnosis. There should also be a focus on 
enhancing primary care provider education on MGUS follow-up. 
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Although MGUS is asymptomatic and incidentally diagnosed, there appear to be 
several characteristics, both biological and behavioral, that distinguish this patient 
population from patients without an MGUS diagnosis. The findings of this dissertation 
work shed light on this understudied premalignant condition and its impact on healthcare 
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Supplemental Table 1. ICD-9 and ICD-10 codes used to calculate the Charlson Comorbidity Index among 
MGUS cases diagnosed 2007-2014. 
Conditions ICD-9 ICD – 10 
Myocardial infraction 410-410.92, 412 I21-I22.9, I25.2 
Congestive heart disease 428-428.9 I50-I50.999 
Peripheral vascular disorder 440.20-440.24, 440.31 440.32, 
440.8, 440.9, 443.9, 441-441.9, 
785.4, V43.4, V43.4 
I70-I71.9, I73.01, I73.1, I73.9, I79.0, I96, 
Z95.8-Z95.9 
Cerebrovascular disease 430-438.9 G45-G46.999, I60-I69.999 
Dementia 290-290.9 F00-F03.999, F05-F05.999 
Chronic pulmonary disease 490-496, 500-505, 506.4 J40-J47.999, J60-J67.999, J68.4 
Rheumatologic disease 710.0, 710.1, 710.4, 714.0-714.2, 
714.81, 725 
M05-M06.999, M32-M34.999, M35.3 
Peptic ulcer disease 531-534.91 K25-K28.999, K56.60 
Mild liver disease 571.2, 571.5, 571.6, 571.4-
571.49 
K70.0-K70.31, K73-K74.999, K75.4   
Diabetes 250-250.33, 250.7-250.73 E10.10-E10.11, E10.51-E10.52, E10.59, 
E10.641, E10.65, E10.69, E10.9, E11.00 -
E11.01, E11.51-E11.52, E11.59, E11.641, 
E11.65, E11.69, E11.9, E13.00-E13.01, 
E13.10-E13.11, E13.51-E13.52, E13.59, 
E13.641, E13.9 
Diabetes with chronic 
complications 
250.4 -250.63 E10.2-E10.5, E10.61-E10.619, E11.2-
E11.5, E11.61-E11.619, E13.2-E13.5, 
E13.61-E13.619 
Hemiplegia or paraplegia 344.1, 342-342.92 G04.1, G81-G82.999 
Renal Disease 582-582.9, 583-583.7, 585-586, 
588-588.9 
N03.0-N03.9, N05.2-N05.5, N05.9, N06.2 
-N06.5, N07.2-N07.5, N08, N17.1-N17.2, 
N18.1-N18.6, N18.9, N19, N25.0, N25.1, 
N25.81, N25.89, N25.9 
Malignancy, including 




C41.999, C43-C43.999, C45-C45.7, C46-
C58.999, C60-C76.999, C81-C85.999, 
C86-C86.999, C88-C88.999, C90-
C97.999, D03.0, D03.10-D03.12, D03.20-
D03.22, D03.30, D03.39, D03.4, D03.51-
D03.52, D03.59, D03.60-D03.62, D03.70-
D03.72, D03.8, D03.9, D45 
Moderate or severe liver 
disease 
572.2-572.8, 456.0-456.21 I85.00-I85.01, I85.10-I85.11, K70.41, 
K71.11-K72.01, K72.10-K72.11, K72.90-
K72.91, K76.6 -K76.7 
Metastatic solid tumor 196-199.1 C45.9, C77-C80.999 




Supplemental Table 2. Sociodemographic and clinical characteristics at MGUS 
diagnosis of patients with an EHR-validated MGUS diagnosis  
Characteristic Patients with MGUS (n=154) 
Men, n (%) 78 (50.6) 
Age at index date (Mean ± S.D.), years 75.6 ± 10.3 
Race, n (%)  
     Non-Hispanic White 131 (99.2) 
     Non-Hispanic Black 1 (0.8) 
Socioeconomic index, n (%) a  
     Low 35 (39.3) 
     Medium 27 (30.3) 
     High 27 (30.3) 
Tobacco use, n (%)  
     Never 51 (36.2) 
     Current smokers 19 (13.5) 
     Quit/Former/Passive Smokers 71 (50.3) 
Current alcohol use, n (%) b 56 (46.7) 
Body mass index, n (%)  
     Underweight (<18.5 kg/m2) 4 (3.1) 
     Normal (18.5-25 kg/m2) 38 (29.7) 
     Overweight (25-30 kg/m2) 43 (33.6) 
     Obese (≥30 kg/m2) 43 (33.6) 
Previous cancer diagnosis, n (%) c  
     Breast (among women) 4 (5.3) 
     Prostate (among men) 5 (6.4) 
     Other 4 (2.6) 
Charlson comorbidity index, n (%) d  
     0 45 (29.2) 
     1 27 (17.5) 
     ≥ 2 82 (53.2) 
     Mean ± SD 2.2 ± 2.2 
Mean serum Cr levels, (± S.D.), mg/dl e 1.3 ± 0.9 
Mean serum Hgb levels, (± S.D.), mg/dl f 12.6 ± 1.4 
May not total 100% due to rounding. Cr=creatinine; Hgb= Hemoglobin. Missing values: Race (n=22), socioeconomic status index 
(n=65), tobacco (n=13), alcohol (n=34), body mass index (n=26) a Tertiles of factor score of median household income, median house 
rent, percentage of the population living below 150% of the poverty line, education index, and percent unemployed; b Current vs 
never; c presence of ICD-O-3 code in tumor registry data prior to MGUS diagnosis; d Using a modified Charlson score with 15 




Supplemental Figure 2. Three multi-trajectory groups of creatinine and hemoglobin values defined among 154 validated 




The dotted-line (----) represents the cut-off point for the definition of abnormal values for each biomarker. Renal insufficiency 
is defined as creatinine (Cr) levels >2 mg/dl. Anemia is defined as hemoglobin (Hgb) levels <10 mg/dL.  
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normal - Hgb 
High Cr/ 
borderline Hgb 
Total, n (%) 136 (88.3) 15 (9.7) 3 (1.9) 
Men, n (%) 66 (48.5) 10 (66.7) 2 (66.7) 
Age at index date (Mean ± S.D.), years 75.7 ± 10.5 74.3 ± 9.7 77.7 ± 6.9 
Race, n (%) 
   
     Non-Hispanic White 120 (99.2) 9 (100) 2 (100) 
     Non-Hispanic Black 1 (0.8) 0 0 
Socioeconomic index, n (%) a    
     Low 32 (39.5) 2 (28.6) 1 (100) 
     Medium 23 (28.4) 4 (57.1) 0 
     High 26 (32.1) 1 (14.3) 0 
Tobacco use, n (%)    
     Never 46 (36.8) 4 (30.8) 1 (33.3) 
     Current smokers 15 (12.0) 3 (23.1) 1 (33.3) 
     Quit/Former/Passive Smokers 64 (51.2) 6 (46.1) 1 (33.3) 
Current alcohol use, n (%) b 53 (48.2) 3 (37.5) 0 
Body mass index, n (%)    
     Underweight (<18.5 kg/m2) 4 (3.4) 0 0 
     Normal (18.5-25 kg/m2) 37 (31.6) 1 (11.1) 0 
     Overweight (25-30 kg/m2) 38 (32.5) 4 (44.4) 1 (50.0) 
     Obese (≥30 kg/m2) 38 (32.5) 4 (44.4) 1 (50.0) 
Previous cancer diagnosis, n (%) c    
     Breast (among women) 4 (5.7) 0 0 
     Prostate (among men) 5 (7.6) 0 0 
     Other b 2 (1.5) 1 (6.7) 1 (33.3) 
Charlson comorbidity index, n (%) d    
     0 42 (30.9) 3 (20.0) 0 
     1 27 (19.8) 0 0 
     ≥ 2 67 (49.3) 12 (80.0) 3 (100) 
     Mean ± SD 1.9 ± 2.0 3.8 ± 2.8 5.0±3.0 
Serum Cr, (Mean ± S.D.), mg/dl e 1.1 ± 0.3 2.2±0.4 6.1±3.8 
Serum Hgb, (Mean ± S.D.), mg/dl f 12.7 ±1.4 11.7 ± 1.0 11.1 ± 1.0 
May not total 100% due to rounding. Cr=creatinine; Hgb= Hemoglobin. Missing values: Race (n=22), socioeconomic status index (n=65), tobacco (n=13), alcohol 
(n=34), body mass index (n=26) a Tertiles of factor score of median household income, median house rent, percentage of the population living below 150% of the 
poverty line, education index, and percent unemployed; b Current vs never; c presence of ICD-O-3 code in tumor registry data prior to MGUS diagnosis; d Using a 
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Supplemental Table 1. Current Procedural Terminology codes of healthcare services evaluated, 
and services used to define MGUS follow-up. 
Healthcare service CPT Codes 
Emergency department visits 99281, 99282, 99283, 99284, 99285 
Hospital visits 99221, 99222, 99223, 99238, 99239 
Office or outpatient visits 
99201-99205, 99211- 99215, 99241- 99245, 








INTERVIEW PROTOCOL FOR PROVIDERS 
This document is to be used as a discussion guide during the interview session. It should 
not be used verbatim as a questionnaire. The questions and probes may be used differently 
depending on the participant feedback and level of comfort with the process. The 
interviewer may ask probing or follow up questions to more fully explore or clarify issues 
brought up on a given question or over the course of the entire interview. 
Welcome 
Intent: The goal of section 1 is to greet the participant, explain the study and obtain verbal 
consent.  
- Greeting the participant: “Hello, my name is _____ and I will be talking with you 
about MGUS”.  
- Thank the participant for talking the time to participate in our study: “Thank you 
very much for being a part of this study and taking the time to speak with me today” 
• Explain the study: “Just as a reminder, our goal is to understand how a diagnosis 
of MGUS affects healthcare utilization” 
• Review informed consent and obtain verbal consent 
• Explain that we will be audio-recording the interview so we can gather more 
information from their stories later.  
“First, we need to complete the consent process. I’d like to record this interview if 
that’s ok with you.   We will store the de-identified transcript on our password 
protected computer.”  
• Inform participant that recorded data is in no way linked to the study subject and 




o Ask participant to refrain from using names – particularly names of patients 
– during the recording  
• Initiate recording “I am now turning on the recorders.” 
o Turn on recording.  
o Begin the recording by stating the date and time. 
o Confirm permission to record the encounter.  
 “This is subject ID number 001 and the interview date is April XX, 2020” 
Experiences with MGUS 
• So you are [fill in what you believe to be their role – e.g., primary care physician]?  
Is that right? 
• And how long have you been in practice? 
• Tell me about your experience with patients with MGUS. About how many patients 
with MGUS do you see in a year?    
• And how do you take care of these patients?  What, if anything, do you do for 
patients with MGUS due to that diagnosis?   
• Probe: Do you have a specific patient management plan for patients with MGUS?  
• Do you recommend certain screenings or other testing related to MGUS 
surveillance? 
• How much does your approach or your management strategy vary across patients 
with MGUS? 
o Probe: How does your care of one patient with MGUS differ from your care 
of another patient with MGUS? 
o What factors influence your management strategy for your patients with 
MGUS? 
Factors that may influence healthcare utilization 
• In general, do you see patients with MGUS having more or different needs for 
healthcare compared to patients of similar age, gender, background who don’t have 




o It’s my understanding that MGUS is more common amount adults aged 50 
and older. Does patient age affect how you care for patients with MGUS? 
o What about patient sex?  Does that affect your management plan?   
o Could you describe to me how a MGUS patients’ level of education may 
impact the care you offer?  
▪ How would you explain the condition (MGUS) to someone with a 
low health literacy level? 
• What preventative, diagnostic, or general healthcare services do you think are most 
important for patients with MGUS?  
o Do you think patients with MGUS need any special counseling due to their 
diagnosis? 
o What kinds of emotional responses and issues related to coping have you 
seen in MGUS patients?  Have any required additional mental health 
referrals?  (probe for details) 
• What barriers do you think exist to providing those services? On the provider, clinic 
or system side? On the patient side?  
o Do you think a MGUS patient’s social networking, support networks, family, 
and friends, influence their own healthcare utilization? (probe for details) 
o How do you think health insurance status affects the care provided to patients 
with a MGUS diagnosis?  
o What aspects of a patient’s overall health status and need for medical care affect 
service utilization in patients with MGUS? (Probe for details) 
Closing and follow up 
We are about to end the interview. Is there anything you’d like to add about how you care 
for patients with MGUS?  Or their needs for or use of healthcare services related and 
unrelated to MGUS? 
Do you have any questions for me? 




TURN OFF RECORDER. 
I appreciate all the information and feedback you have given me. Your answers will help 
us understand the healthcare utilization of patients with MGUS.  
• Thank the provider for their valuable contribution to this research. 
• Immediately after the interview (after you have left the participants’ area or ended the 
phone interview), write down any general reflections about the interview, thoughts 
about the participants attitudes or reactions, or any other potentially pertinent info.  
Demographic Data Sheet  
Subject ID: ___________________    Date: 
________________________ 
Race/ethnicity 
□ American Indian/Alaska Native 
□ Asian 
□ Black/ African American 
□ Hispanic or Latino 




□ Male □ Female  □ _________________ 
Years in Practice: ________________ 
Type of provider:  




□ Primary care physician 
□ Oncologist 
Other ________________ 
INTERVIEW PROTOCOL FOR PATIENTS  
This document is to be used as a discussion guide during the interview session. It should 
not be used verbatim as a questionnaire. The questions and probes may be used differently 
depending on the participant feedback and level of comfort with the process. The 
interviewer may ask probing or follow up questions to more fully explore or clarify issues 
brought up in a given issue, or over the course of the entire set of interviews. 
Welcome 
Intent: The goal of section 1 is to greet the participant, explain the study and obtain verbal 
consent.  
- Greeting the participant: “Hello, my name is _____ and I will be talking with you 
today about MGUS.”  
- Thank the participant for talking the time to participate in our study: “Thank you 
very much for being a part of this study and taking the time to be here today” 
• Explain the study: “As a reminder from the materials you’ve seen already, the 
purpose of this interview is to enable us understand what it is like to be diagnosed 
with MGUS, and how that affects your healthcare, for example, how often you see 
your doctor and what tests have been done” 
• Review informed consent and obtain verbal consent 
• Explain that we will be recording the interview, so we can gather more information 
from their stories later.  
“First, I want to be sure that you understand what we are doing and that your 
privacy will be protected. This interview will be recorded. All data will be stored 
on our secure, password protected computer. The recording of our conversation 




included, and only the people working on this study will be able to see or hear what 
you say.” 
o Inform participant that their name will not be included in the recording or 
transcript 
o Ask participant to refrain from using their own name and/or the real names 
of others during the recording  
“There are no right or wrong answers. Please respond according to what 
applies to you and if there is any question that you prefer not to answer, please 
let me know and we can move on to the next question. Do you have any 
questions before we begin?” 
• Initiate recording “I am now turning on the recorders.” 
o Turn on the two recorders. 
o Begin the recording by stating the date and time. 
o Confirm permission to record the encounter.  
 “This is subject ID number 001 and the interview date is April XX, 2020” 
Experiences with MGUS and overall health 
• First, I’d like to understand a bit about your current health. How would you describe 
your overall health?    
o Do you have any medical problems or conditions that are concerning to 
you?  Or that interfere with your day to day life?   
• Now I’d like to hear about what it was like for you to be diagnosed with MGUS. 
o When were you first told that you have MGUS? 
o Tell me about how you were diagnosed. 
o Did you have any symptoms at that time?  
o What was it like for you to receive that diagnosis? 





o If you were to explain what it means to have MGUS to someone who had 
never heard of it, how would you explain it?   
o Has this diagnosis had an impact on your day to day life?   
o Has this diagnosis affected your ability to do the things you want to do or 
need to do? 
• Can you tell me how you feel about your MGUS diagnosis?  
o So you were diagnosed about [x months/years] ago. What has it been like 
for you over the past x time?   
o Do you feel worried about your MGUS diagnosis?  
o (If yes, ask) How might this fear affect when you decide to go to the doctor? 
(whether you go more because of this scare – or do you avoid the doctor?) 
o What does a MGUS diagnosis mean to you? – can you tell me more about 
that? 
Factors that may influence healthcare utilization 
• Have you tried to find information on MGUS, no including healthcare providers 
(like doctors, nurses, etc)?  [if yes, then continue]  
• Where have you looked, or who have you asked for information? Have you done 
any research on the internet?  Tell me about what sort of research you have done. 
What kinds of information were you looking for?  And were you able to find what 
you needed?  
• Now I am going to ask about treatment and medical care. 
• Tell me about how this diagnosis has changed – or not changed – your healthcare. 
By healthcare I mean what medications you take, how often you see a doctor, what 
doctors you see, and what tests you have done, such as imaging scans or blood tests. 
• Have you had any treatments for MGUS specifically?    
• Has having a diagnosis of MGUS affected any treatments you might have for other 
conditions? 
• Have you had any additional testing related to having MGUS after being 
diagnosed?   





o Are there services or types of care that you use more since your diagnosis?  
Tell me about more about that. 
o Are there services that you stopped using or are using less since your 
diagnosis? 
• There are a lot of things that affect whether and how people get healthcare. What 
do you think influences whether and how you get care?   
o What about MGUS?  How much does this diagnosis influence the care you 
receive? 
o Do you have other chronic conditions that require frequent doctor visits or 
tests? 
o Any other health services that you use for chronic conditions?  
o What factors like family, work, etc do you think may affect the quality of 
care for patients with MGUS? 
• How does your current income influence the care you seek or receive as a patient 
with MGUS? Tell me more about this. 
• How does your health insurance status affect the care you receive as a patient with 
MGUS?  
• How does your medical provider affect the care you receive as a patient with 
MGUS?  
• Do you think your social network, including family and friends, influence your use 
of healthcare services? 
• How does your social support network affect how you use healthcare services? Do 
you use more or fewer health services because of this support? 
• Has your social support network always been the same? Or has it changed since the 
MGUS diagnosis? 
• Do you believe your age and/or sex has an effect on the healthcare services you 
use?  
• In what ways does your race or ethnicity affect the overall healthcare you have 




• Could you describe how your education level may impact your overall healthcare 
since you were diagnosed with MGUS? 
Closing and follow up 
We are just about done. Do you have anything else you would like to say about what it’s 
like to have MGUS? Or about your interactions with healthcare providers and the 
healthcare system in general? 
Do you have any questions for me? 
Thank you for participating in this interview. I’m going to shut off the recorder now. 
TURN OFF RECORDER. 
Thank you again for talking with me!  It’s been very helpful.  
• Immediately after the interview (after you have left the participants’ area or ended the 
phone interview), write down any general reflections about the interview, thoughts 
about the participants attitudes or reactions, or any other potentially pertinent 
information.  
Demographic Data Sheet  
Subject ID: ___________________     
Date: ________________________ 
How do you identify yourself in terms of race and ethnicity?  □ American Indian/Alaska 
Native 
□ Asian 
□ Black/ African American 
□ Hispanic or Latino 






And in terms of Gender:  
□ Male □ Female  □ _________________ 
What is the highest level of education you completed: 
□ Some high school 
□ High school graduate 
□ Some college 
□ Associate degree 
□ Bachelor’s degree  
□ Graduate school 
□ Doctorate/professional degree (_________________) 
 
Family History: 
Has anyone in your immediate family been diagnosed with any of the following conditions 
(e.g., parents, siblings, children) 
□ Multiple myeloma if yes, who? 
□ Smoldering myeloma if yes, who? 
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